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Abstract
NUCLEAR RECEPTOR EXPRESSION AND CHARACTERIZATION OF
THE MAJOR RETINOIC ACID TARGET GENE IN MELANOMA

Linda L. Eastham

Malignant melanoma is the primary cause of death from all diseases arising
from the skin and it is one of the most resistant tumors to standard treatment
options. The increasing incidence of melanoma and its poor prognosis makes the
understanding of melanoma cell biology very important. Melanoma progression
is a complex, multi-step process, and the molecular events leading to melanoma
tumor cell proliferation and invasion still need further examination. This study is
focused on measuring the expression and activity of two specific genes and their
protein counterparts that are altered during melanoma progression.

It also

examines the mechanism through which Vitamin A induces melanoma cell
differentiation and inhibits tumor cell growth.
The first part of this research focused on a family of ligand activated
transcription factors, the PPARs (Peroxisome Proliferator-Activated Receptors). I
examined the expression and activity of PPARs and the effects of PPARα and γ
agonists on the growth of mouse melanocytes and melanoma cells. I found
increased expression of PPARα and γ protein levels in B16 mouse melanoma
cells compared to mouse melan-a melanocytes.

xv

PPARγ-selective agonists,

prostaglandin J2, troglitazone and ciglitazone, were able to inhibit growth of both
melan-a and B16 cells. The only effective PPARα agonist was leukotriene B4
and it was only able to inhibit melan-a cell growth. PPAR transcriptional activity
was examined by reporter gene activity and I found a correlation between
activation of the receptor and its ability to inhibit cell growth.
The second part of my thesis work examines the expression and function of an
indirect target gene of atRA stimulation, AKAP12. This protein functions as a
scaffold, assembling a multi-protein complex containing enzymes involved in
regulating the activity of various signaling pathways.

Results show atRA

treatment of mouse and human melanocytes and melanoma cells increased
AKAP12 expression, and this change was modulated by the transcription factor
AP-1. I found a significant correlation between atRA induction of AKAP12
mRNA and the ability of atRA to inhibit growth.

Functional studies using

AKAP12 siRNA to decrease the level of this protein indicate that AKAP12
contributes to the ability of melanoma cells to invade and grow in an anchorageindependent manner.

xvi

Chapter1: Introduction_______________________
Melanoma
Cutaneous malignant melanoma (CMM) is a deadly cancer of the skin. It
arises from melanocytes, located in the basal layer of the epidermis. These cells
produce the pigment melanin, which is not only responsible for the coloration of
hair and skin, but has photoprotective qualities enabling it to protect skin cells
from UV-induced DNA damage. Melanocytes are derived from cells of the
neural crest and are also located in tissues such as brain, inner ears, heart and eyes
(Santiago-Walker, et. al., 2008).
The incidence of melanoma worldwide has been rising for the past three
decades and it is the sixth most diagnosed cancer in the USA (Boyle, 2011;
www.cancer.org). This year (2012), it is estimated that 70,250 Americans will be
diagnosed with melanoma. Early diagnosis leads to surgical removal of the tumor
and results in an average 5 year survival rate of 93%.

However, once the

melanoma has metastasized, there is an extraordinarily poor survival rate with
<10% of patients surviving after 5 years (Boyle, 2011). Until recently, the only
FDA-approved drug for the treatment of malignant melanoma was the alkylating
agent dacarbazine (DTIC), which only induced complete remission in 5-10% of
patients.

Combination therapies using nitrosoureas (carmustine, lomustine),

taxanes (taxol, docetaxol), platinum-associated drugs (cisplatin, carboplatin), IL-2
and/or IFN-α have also failed (Boyle, 2011; Soengas and Lowe, 2003). However,
within the past year, two new therapeutic agents have been shown to inhibit the
growth of metastatic melanoma and extend patient lifespan. The first new FDA-

-1-

approved agent is the monoclonal antibody ipilimumab. It is currently given to
treat patients with late stage melanoma that has metastasized or cannot be
removed by surgery. This antibody binds to cytotoxic T lymphocyte-associated
antigen 4 (CTLA-4). It plays an important regulatory role in the immune system.
This immunoglobulin is expressed on the surface of helper T cells and transmits
an inhibitory signal to T cells, suppressing the immune system’s T cell response.
The second FDA-approved compound is the BRAF inhibitor PLX4032
(vemurafenib). BRAF is a protein kinase that regulates the mitogen-activated
protein kinase (MAPK) pathway involved in regulating cell proliferation. This
drug targets the V600E (valine to glutamate) activating mutation commonly seen
in this protein. This class of drugs has been shown to delay the progression of
advanced melanoma, improving overall patient survival (Guida, et. al., 2012).
After melanoma has been diagnosed, tests are done to find out if the melanoma
cancer cells have spread within the skin or to other parts of the body. Staging is
performed to determine how widespread the melanoma has become.

This

diagnosis takes into account information on tumor thickness (T) (Breslow
measurement), whether the melanoma has spread to the nearby lymph nodes (N),
and whether it has metastasized (M) and to which organs it has reached. A biopsy
of the tumor is performed and the thickness is measured under a microscope. The
Breslow thickness is a major predictor of prognosis in CMM. The thinner the
melanoma, the better the prognosis will be (Osborne and Hutchinson, 2001).
Melanomas less than 1mm in depth have a very small chance of spreading. As
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the

melanoma

becomes

thicker,

the

chance

of

spreading

increases

(www.cancer.org).
Several factors have been identified that play a role in melanoma formation
and they can be divided into two categories: environmental factors and host
factors (Boyle, 2011). Exposure to UV radiation, usually from the sun, is the
most important environmental risk factor for developing malignant melanoma.
UV radiation is composed of both UVA (320-400nm) and UVB radiation (280320nm).

Although UVA is the major component of UV radiation and can

penetrate the deepest, it is the UVB fraction that is mainly responsible for the
development of skin carcinomas (Oikarinen, et. al., 1991; Benjamin, et. al.,
2007).
There are also several host factors that are associated with increased risk.
These include a family history of melanoma, a large number of benign or
dysplastic nevi, mutations in the CDKN2A (p16INK4a-ARF) gene and variation in
the melanocortin-1 receptor (MC1R) genotype that leads to increased sensitivity
to UV radiation (Boyle, 2011; Benjamin, et. al., 2007; Melnikova and Bar-Eli,
2008).
The process of melanoma progression involves the sequential accumulation of
a series of genetic alterations that drive cellular transformation. The melanoma
tumor cells evolve through three distinct phases of growth. In the radial growth
phase (RGP), the tumor grows laterally, and although cells may invade the
dermis, they do not form a nodule. In the vertical growth phase (VGP), the cells
grow vertically, invading the underlying tissues and forming a true tumor
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(Hussein, 2004; Vladislova and Bar-Eli, 2008; Bennett, 2008). In the metastatic
phase (Met), the transformed cells are able to invade and spread to distant target
organs such as the lungs, liver, gallbladder, brain and bones.
Many signaling pathways also become dysregulated during melanoma
development. The most common mutations are those that constitutively activate
the proteins NRAS and BRAF.

Activating mutations in these proteins are

mutually exclusive, with approximately 20% of tumors having NRAS mutations
and 50-70% of tumors having BRAF mutations (Wagner and Fisher, 2005;
Haluska, et. al., 2006; Benjamin, et. al., 2007; Bennett, 2008; Boyle, 2011).
These proteins drive the MAPK pathway, which is a crucial pathway involved in
the regulation of cellular proliferation and differentiation. The PTEN/PI3K/AKT
pathway is also altered. Inactivating mutations in the tumor suppressor PTEN are
common in melanoma and seem to be prevalent in tumors harboring a BRAF
mutation (Wagner and Fisher, 2005; Haluska, et. al., 2006; Benjamin, et. al.,
2007; Boyle, 2011).

The β-catenin pathway is also abnormally regulated in

approximately 30% of melanoma tumors (Haluska, et. al., 2006; Bennett, 2008).
β-Catenin, complexed with the transcription factors LEF and TCF can upregulate
c-myc and cyclin D1, suppress apoptosis and upregulate the transcription factor
MITF, a master regulator of melanocyte linage. This factor is responsible for
regulating melanocyte proliferation, differentiation and survival (Wagner and
Fisher, 2005; Bennett, 2008; Mitra and Fisher, 2009). In addition, up-regulation
of the transcription factor NF-κB is also found in melanoma tumors (Bennett,
2008; Melnikova and Bar-Eli, 2008). This factor regulates pathways involved in

-4-

inflammation, cell cycle regulation, apoptosis and oncogenesis.

Constitutive

activation of NF-κB is found in melanoma and supports cancer cell survival
because it is involved in reducing the sensitivity of melanoma cells to
chemotherapeutic drugs. It is also linked to the constitutive activation of AKT
(Bennett, 2008; Melnikova and Bar-Eli, 2008). The transcription factors STAT3
and STAT5 (signal transducers and activators of transcription), have also been
shown to respond to oncogenic stimulation by growth factors or non-receptor
tyrosine kinases. They are involved in the down-regulation of anti-apoptotic
genes such as Bcl-XL. The activity of STAT3 and 5 are often up-regulated in
melanoma (Melnikova and Bar-Eli, 2008). In addition, melanomas are usually
resistant to external inducers of apoptosis, including TNF-α, FasL and TRAIL.
The intrinsic apoptotic activator APAF-1 is silenced in advanced melanomas
(Soengas and Lowe, 2003; Bennett, 2008).
Migration and metastasis of melanoma cells mimics a physiologic process
called EMT (epithelial mesenchymal transition). During this process cells lose
their cell-cell and cell-matrix connections and acquire the motile, migratory
properties of mesenchymal cells. There is also a down-regulation of the cell
adhesion protein E-cadherin and an upregulation of N-cadherin. EMT conversion
confers metastatic and invasive properties to melanoma cells. The transcription
factors SNAIL and SLUG contribute to this process. Over-expression of SNAIL
suppresses expression of E-cadherin and SLUG activity is essential for melanoma
metastasis (Haass, et. al., 2005; Bennett, 2008; Girouard and Murphy, 2011).
This information reveals that there are many pathways that are dysregulated in
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melanoma, and these altered pathways drive the formidable aggressiveness of this
cancer.

Vitamin A
Vitamin A is a fat-soluble co-factor present in food that is essential for life.

It

plays an important role as a coenzyme in vital processes that the body needs to
function normally.

The structure of Vitamin A makes it good molecule for

trapping light energy. It is the molecule responsible for transferring light energy
into a chemical nerve impulse in the eye (Amann, et. al., 2011).

It is also

important for the regulation of biological activities such as embryogenesis, cell
growth, differentiation, reproduction, apoptosis, and bone formation. (Niles, 2000;
Sun and Lotan, 2002; Mamede, et. al., 2011).
Physiological metabolites of Vitamin A are collectively known as retinoids.
Although the most common dietary form of Vitamin A is retinol, there are over
4000 natural and synthetic molecules that are structurally and/or functionally
related to this compound. Vitamin A is only obtained through the diet in the form
of retinol, retinyl esters, or proVitamin A (β-carotene). It is found in foods of
plant origin such as sweet potatoes and carrots as β-carotene and in animal
products such as liver and eggs as retinyl esters (Amann, et. al., 2011).

-6-

A. Retinol

B. all-trans Retinoic Acid

C. Beta-Carotene

Figure 1.1. Chemical structures of A) retinol, B) all-trans retinoic acid, and C)
beta-carotene.

Retinol is either stored in the liver as retinyl esters or circulates in the
bloodstream complexed with plasma retinol-binding protein (RBP) or
transthyretin (pre-albumin). Plasma membrane receptors for the retinol-binding
protein mediate the cellular uptake of retinol. After retinol has been taken up by
the cell, it becomes bound to cellular retinol-binding protein (CRBP). Retinol is
first converted to retinal, before being metabolized into all-trans retinoic acid
(atRA) by a retinal dehydrogenase. The major physiologically active metabolite
of retinol, retinoic acid, becomes bound to cellular retinoic acid-binding protein
(CRAPB).

The CRABP bound retinoic acid is then delivered to the nucleus of

the cell by CRABPII, where it will bind to and activate the retinoic acid receptor.
(Niles, 1998).
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Figure 1.2. Retinol metabolism in the body. Retinol is first converted to alltrans retinaldehyde by alcohol dehydrogenases or short-chain dehydrogenases
before being converted to all-trans retinoic acid by aldehyde dehydrogenases
(Perlmann, 2002).

Retinoic Acid Regulated Gene Expression
Retinoids exert their effects on biological processes through the regulation of
gene expression, which is due to the ability of atRA to bind and activate specific
nuclear receptors.

There are two distinct sub-families of nuclear retinoid

receptors. The first are the RARs (retinoic acid receptors) that bind all-trans
retinoic acid and 9-cis retinoic acid. The RXRs (retinoid X receptors) bind only
9-cis retinoic acid. There are three distinct subtypes of RXRs and RARs (α, β
and γ), which are encoded by different and highly conserved genes.
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Figure 1.3. Functional domains of steroid receptor proteins. The A/B region is
the ligand-independent activation domain, the C region is the DNA-binding
domain, the D region acts as a hinge, while the E/F region contains the ligand
binding domain.

The RARs share functional domains common to other members of the steroid
hormone receptor gene family. The A/B region located in the N-terminal portion
functions as a ligand-independent transcriptional activation domain. The C region
contains the DNA-binding domain that consists of two zinc-binding, cysteine-rich
segments. The D domain acts as a hinge, whereas the E segment acts as a
dimerization interface for ligand-dependent transcriptional activation. This region
is highly conserved between all of the RAR subtypes. The C-terminal F region is
different between the RAR subtypes and at the present time its function is not
known. However, it is thought that it may bind the coactivator CBP/p300 (Niles,
1998).
Retinoic acid induces phenotypic changes in target cells by inducing the
transcriptional activity of the nuclear retinoid receptors. It is the main activator of
RARs whereas the RXR serves as its common heterodimeric partner. The RXRs
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have the ability to also heterodimerize with other nuclear receptors.

These

include the thyroid hormone receptor (TR), Vitamin D receptor (VDR), PPARs
(peroxisome-proliferator activated receptors), and numerous orphan receptors.
The RAR-RXR heterodimer binds to a specific sequence located in the promoter
region of the DNA called a retinoic acid response element (RARE) with a half site
sequence similar to AGGTCA. It is a direct repeat (DR) of half sites with a
spacer of 2 to 5 nucleotides (DR2-DR5). In the absence of ligand, the RAR-RXR
dimer is bound to the RARE, and held inactive by co-repressors, such as SMRT
(silencing mediator of retinoid and thyroid signaling) and N-CoR (nuclear
receptor co-repressor). These co-repressors bind to the non-liganded receptors
resulting in suppression of basal transcriptional activity. The ability of atRA to
bind to the RARs results in destabilization of this complex and a conformational
change in the receptors that allow for the disassociation of co-repressors and
binding of co-activators, such as SRC-1 (steroid receptor co-activator 1) and
CBP/p300. Consequently, atRA exerts its effects through changing the structure
of the receptor, which allows for control of distinct molecular events at retinoidregulated promoters (Niles, 1998).
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Figure 1.4 Modulation of RA induced gene activity by the RAR. The RAR/RXR
heterodimer mediated the effects of RA. In the absence of ligand (RA), the
heterodimer complex is bound to DNA at its retinoic acid response element
(RARE) and also bound to co-repressors. This complex induces transcriptional
repression through histone deacetylation.

Binding of ligand (RA) induces a

conformational change that leads to binding of co-activators and histone
acetylation, which induces gene activation. Hox genes are targets of RA induced
activity during mammalian embryonic development. These genes are responsible
for the determination of the basic structure and orientation of an organism
(Marletaz , et. al.,2006).

An important regulatory mechanism that co-activators and co-repressors have
is that they harbor histone acetylation/deacetylation enzyme activity. Acetylation
of lysine residues on nucleosome tails results in the relaxation of the chromatin
structure, allowing access of transcription factors to DNA and therefore, an
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increase in transcriptional activity. Co-activators, such as CBP/p300, contain
histone acetyl-transferase (HAT) activity while co-repressors recruit enzymes that
have histone deacetylase (HDAC) activity. The level of acetylation is controlled
by these two opposing families of enzymes, and ultimately, the activity of the
RAR/RXR complex.

Retinoids and Cancer
Retinoids have been used as both chemopreventative and chemotherapeutic
agents for the treatment of many types of cancers. Studies using Vitamin Adeficient animals showed that there was a strong connection between deficiency
and the susceptibility to cancer (Chambon, 1994; Sporn, et. al., 1976). The
addition of retinoic acid to the media of various types of cancer cells grown in
culture was able to significantly reduce proliferation (Niles, 2000; Bushue, et. al.,
2010).

Retinoic acid can induce differentiation in tumor cells such as

neuroblastoma (Sidell, 1982), melanoma (Wood, et. al., 1990; Fligiel, et. al.,
1992; Jacob, et. al., 1998; Niles, 2003), and promyelocytic leukemia (Breitman,
et. al., 1980). Retinoids are able to elicit their effects on malignant cell growth
through the regulation of cell growth, differentiation, and apoptosis (Lotan, 1995;
Bushue, et. al., 2010; Mamede, et. al., 2011).
There is evidence that demonstrates a connection between cellular
transformation and altered expression of RARs. It is believed that the RAR-β2
receptor is critical for mediating the growth inhibitory effects of retinoids and its
down-regulation is correlated with the loss of atRA’s ability to inhibit cell growth
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(Lotan, 1996; Sun, 2004; Pavan, et. al., 2006; Bushue, et. al., 2010).

The

expression of this receptor is down-regulated in head and neck cancer, melanoma,
breast, and oral cancers (Lotan, 1995; Fan, et. al., 2010). The reactivation of
RAR-β2 expression leads to reacquisition of atRA’s ability to inhibit cell growth
(Xu, 2007), therefore it has been considered as a tumor suppressor gene. The
silencing of RAR-β2 expression is due to epigenetic changes, mainly DNA
methylation (Virmani, et. al., 2001; Shaw, et. al., 2006). Current research from
our laboratory indicates that, while DNA methylation appears to be the
predominant mechanism for silencing of RAR-β2 expression, there are other
mechanisms by which this occurs, such as modulating the levels of acetylation of
histones H3 and H4 (Fan, et. al., 2010).

Retinoids and Melanoma
A number of synthetic and natural occurring retinoids are available for the
treatment of many skin diseases, including skin cancer (Niles 2002). Several
studies have shown that retinoids, especially atRA, are able to induce
differentiation and growth arrest in both mouse and human melanoma cells
(Jacob, et. al., 1998; Fligiel, et. al., 1992; Huang, et. al., 2002; Niles, 2003).
These effects can happen through a number of mechanisms. In B16 mouse
melanoma cells, atRA inhibits both anchorage-dependent and –independent
growth through inhibition of cell growth at the G1 phase of the cell cycle (Niles,
1987). It also stimulates the production of melanin and induces an increase in
nerve growth factor receptors on the cell membrane. Through suppression of the
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transformed phenotype, retinoids have also been shown to inhibit invasion and
metastasis in human melanoma cells (Wood, et., al., 1990; Jacob, et. al., 1998).
Numerous studies have shown that retinoids have potential in the prevention
and treatment of many cancers. The ability of retinoids to inhibit tumor growth
may be related to changes in specific signaling pathways. However, the complete
mechanism by which they exert their effects still remains poorly understood, and
needs to be studied in greater detail.

PPARs
Peroxisome proliferator-activated receptors (PPARs) are a group of ligandactivated transcription factors and members of the nuclear hormone receptor
superfamily that include the thyroid, Vitamin D, and retinoid receptors. There are
three separate genes that give rise to the different isoforms of PPAR, termed
PPARα, β/δ, γ. Due to differential splicing and alternate promoter usage there are
three isoforms of gamma - γ1, γ2, γ3 (Fajas, et. al., 1998; Desvergne and Wahli,
1999; Roberts-Thomson, 2000). Each of the PPAR isoforms has a different tissue
distribution, function, and to some extent, different ligand specificity. PPARα is
expressed primarily in the liver, heart, kidney, skeletal muscle and brown adipose
tissue. PPARβ/δ expression is ubiquitous, while PPARγ is primarily found in
white and brown adipose tissue, large intestine and spleen (Desvergne and Wahli,
1999).
PPARs function as the body’s fatty acid sensors, regulating genes involved in
lipid and glucose metabolism (Green, 1995; Desvergne and Wahli, 1999; Escher
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and Wahli, 2000; Berger and Moller, 2002).

Endogenous ligands include

palmitic, oleic, linoleic, arachidonic fatty acids, as well as the eicosanoids,
including prostaglandins and leukotriene B4. The synthetic ligands include the
fibrate class of compounds used to treat hyperlipidemia and the thiazolidinediones
that are used to treat type II diabetes (Roberts-Thomson, 2000; Michalik, et. al.,
2004).
Upon activation, PPARs form a heterodimer with the retinoid X receptor. This
complex binds a specific sequence in the promoter region of target genes called a
peroxisome proliferator response element (PPRE).

This sequence is a direct

repeat of a hexameric nucleotide sequence – AGGTCA – separated by one
nucleotide, called a DR-1. This sequence is important in determining PPAR/RXR
binding specificity (Isseman, et. al., 1993; Roberts-Thomson, 2000).

PPRE

elements have been identified in the regulatory regions of many genes involved in
carbohydrate and lipid metabolism (Tontonoz, et. al., 1994; Tontonoz, et. al.,
1995, Schoonjans, et. al., 1996; Fajas, et. al., 1997; Kliewer, et. al., 2001).
PPAR activation up-regulates genes involved in β and ω fatty acid oxidation,
such as acyl CoA oxidase and cytochrome P450 isotypes (Tugwood, et. al., 1992;
Aldridge, et. al., 1995). These receptors are also the target for the fibrate class of
drugs used to treat hyperlipidemia (Forman, et. al., 1997; Kliewer, et. al., 2001).
PPARγ activation is involved in adipocyte differentiation, as well as glucose and
fatty acid storage (Rosen, et. al., 1999; Rosen and Spiegelman, 2000; Rosen, et.
al., 2000). This receptor is the target for the thiazolidinedione drugs that are used
as insulin sensitizers for the treatment of type II diabetes (Kletzien, et. al., 1992,
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Rosen and Spiegelman, 2000; Kliewer, et. al., 2001, Rosen and Spiegelman,
2001). The specific role of PPARβ/δ is not defined, but emerging evidence
suggests that it may play a role in other processes, such as promotion of lipid
accumulation in macrophages (Nagy, et. al., 1998; Tontonoz, et. al., 1998;
Vosper, et. al., 2001), differentiation of epithelial cells (Rosenfield, et. al., 1999;
Matsuura, et. al., 1999), keratinocytes (Westergaard, et. al., 2001), adipocytes
(Bastie, et. al., 1999; Bastie, et. al., 2000; Hasen, et. al., 2000), cholesterol
homeostasis (Leibowitz, et. al., 2000; Oliver Jr., et. al., 2001), bone metabolism
(Mano, et. al., 2000), skin wound healing (Michalik, et. al., 2001; Wahli, 2002),
and embryo implantation and decidualization (Lim, et. al., 1999). PPARβ/δ can
be activated by many of the compounds that activate PPARα (Roberts-Thomson,
2000). Specific endogenous ligands that activate this receptor remain unknown,
although there are data to support that the arachadonic acid metabolite,
prostacyclin, can act as an endogenous ligand for PPARβ/δ (Shao, et. al., 2002;
Michalik, et. al., 2003).
Aberrant expression of PPAR receptors has been found in several types of
cancers.

These include colon, prostate, lung, skin, breast, and liposarcomas

(Sarraf, et. al., 1995; Tontonoz, et. al., 1997; Elstner, et. al., 1998; Mueller, et. al.,
1998; Mueller, et. al., 2000; Motomura, et. al., 2000; Thuillier, et. al., 2000;
Suchanek, et. al., 2002; Gupta, et. al., 2004).

Involvement of PPARα in

tumorigenesis is thought to be through induction of cell cycle regulatory genes
such as CDK-1 and 4 and c-myc (Peters, et. al., 1998; Roberts-Thomson, 2000).
Furthermore, there is evidence to suggest that this receptor is involved in
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suppression of apoptosis, which also promotes carcinogenesis (Desvergne and
Wahli, 1999; Roberts-Thomson, 2000). PPARβ/δ has been found to be overexpressed in many human and rodent colorectal cancers and the expression of this
receptor has been shown to be regulated by the adenomatous polyposis coli
(APC)/β-catenin/TCF-4 pathway (He, et. al., 1999; Gupta, et. al., 2000; Park, et.
al., 2001). PPARγ has powerful effects on cellular differentiation and is thought
to act as a tumor suppressor gene (Sarraf, et. al., 1999; Ikezoe, et. al., 2001).
Activation of PPARγ causes inhibition of cell growth and promotes differentiation
in many epithelial derived cancer cell lines (Sarraf, et. al., 1995; Tontonoz, et. al.,
1997; Elstner, et. al., 1998; Mueller, et. al., 1998; Kubota, et. al., 1998; Mueller,
et. al., 2000; Chang and Szabo, 2000).

AKAP12
A kinase anchoring proteins (AKAPs) are a class of structurally diverse but
functionally similar scaffolding proteins.

They were discovered due to their

ability to bind the regulatory subunit of Protein Kinase A (PKA) (Rubin, 1994;
Dell’Aqua and Scott, 1997; Colledge and Scott, 1999; Feliciello, et. al., 2001;
Carlisle-Michel and Scott, 2002). The ability of AKAPs to bind PKA allows the
holoenzyme to be sequestered at specific regions within the cell where it is
exposed to increased levels of cAMP. This allows more efficient activation of the
enzyme and more precise substrate selection. AKAP proteins are involved in
assembling multi-protein signaling complexes that function to promote efficient
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and specific enzyme/substrate reactions in a spatial and temporal manner
(Gelman, 2002).

Figure 1.5. Organization of the AKAP12 gene. The generic gene structure of
mammalian AKAP12 locus. The arched lines connecting the exons represent the
splicing of the three mRNAs encoded by the AKAP12 gene (Streb, et., al., 2004).

Human AKAP12 is also known as AKAP250 or Gravin. Gravin was identified
as the target of an autoantibody in patients with myasthenia gravis and targets the
PKA binding domain of AKAP12 (Nauert, et. al., 1997). The rodent orthologue
is termed SSeCKS (Src-Suppressed C Kinase Substrate) and was discovered in rat
fibroblasts to be down-regulated upon transformation by oncogenic forms of Src
and Ras (Lin, et. al., 1996). The hAKAP12 gene is located on chromosome 6q2425.2, which is a deletion hotspot in advanced prostate, breast and ovarian cancer
(Noviello, et. al., 1996; Cooney, et. al., 1996; Tibilette, et. al., 2000; Tibilette, et.
al., 2001; Gelman, 2002; Abdollahi, et. al., 2003; Gorringe, et. al., 2009).
Therefore, it is believed that the AKAP12 locus may encode a tumor suppressor
gene (Lin, et. al., 2000). The AKAP12 gene is approximately 100kb long and
contains 6 exons. There are 3 distinct gene products, AKAP12α, β, and γ, each
with their own promoter allowing their expression to be independently regulated.
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AKAP12α is the main isoform and the protein contains a myristoylation sequence
that can target it to the cell membrane or endoplasmic reticulum. In addition to
binding PKA, AKAP12 proteins also have docking sites for many other kinases
and adaptor molecules.

These include protein kinase C, phosphatase 2B,

calmodulin, cyclin D and F-actin (Gelman, 2002).

Mechanisms regulating

AKAP12 function are still being explored.

AKAP 12

Figure 1.6. Structure of the AKAP12 scaffolding protein. AKAP12 contains
several PKC phosphorylation sites (pS) as well as various protein binding
domains, including protein kinase A (PKA), protein kinase C (PKC), calmodulin
(CaM),

cyclin

D,

F-actin,

and

GalTase
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(β1,4-galactosyltransferase)

a

transmembrane receptor for laminin. PxxP represents potential SH3 binding sites.
AKAP12 also encodes several nuclear localization sites (NLS) (Gelman, 2002).

The over-expression of AKAP12/SSeCKS in NIH3T3 cells causes inhibition
of cell growth by promoting G1 phase arrest through binding and regulation of
cyclin D activity (Lin, et. al., 2000; Gelman, 2002).

It also promotes re-

organization of the actin-based cytoskeleton that induces cell flattening (Nelson
and Gelman 1997; Gelman, et. al., 1998, Gelman, et. al., 2000; Xia and Gelman,
2002; Cheng, et. al., 2007). This restructuring seems to be modulated through
focal adhesion kinase-dependent tyrosine phosphorylation of AKAP12 (Xia and
Gelman, 2002). In addition, re-expression of AKAP12 causes a down-regulation
of proliferative and pro-angiogenic gene expression, such as VEGF (Su, et. al.,
2006; Liu, et. al., 2006), and also inhibits podosome formation and metastatic
progression in human prostatic cancer (Lin and Gelman, 1997; Xia, et. al., 2001;
Gao and Gelman, 2006). Further evidence for the involvement of this protein in
cancer is provided by the SSeCKS null mice that develop prostatic hyperplasia
(Akakura, et. al., 2008).
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Rationale for Thesis Projects___________________
Melanocytes play a very important role in the normal physiology of the skin.
These cells produce the pigment melanin, which not only affects the visible color
of our skin, but also functions as a photoprotective substance that is able to
dissipate more than 99.9% of absorbed UV radiation as heat. UV radiation is a
potent DNA damaging agent and is a causation of skin carcinogenesis. UVinduced DNA damage in primary cultures of melanocytes showed an increased
frequency of pyrimidine dimers, which are signatures of UV mutation (Mouret, et.
al., 2012). The genes that are principal targets of mutations in melanoma are
commonly oncogenes and tumor suppressor genes. The most frequent mutations
include genes that cause constitutive activation of RAS and RAF proteins,
p16INK4a gene deletions, mutations in the melanocortin 1 receptor (MC1R), PTEN,
and PI3K genes. Mutations in these genes can change the expression and/or
activity of transcription factors. The transcription factor AP-1, as well as the
ligand activated nuclear receptors RARs, RXRs and PPARs have exhibited
altered expression and activity in melanoma cells.
The purpose of my thesis research was to study specific genes and proteins that
changed during melanoma progression.

Specifically, I was interested in

determining whether these altered pathways could be ameliorated by the dietary
component Vitamin A resulting in cancer cell differentiation and loss of
malignancy. I focused initially on a family of ligand activated nuclear receptors,
the PPARs, due to their interaction with RXRs. Subsequently, I studied the gene
AKAP12, which was identified through microarray analysis as exhibiting the
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highest degree of stimulation in atRA-treated melanoma cells. The following
chapters explain the results from these two studies.
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Chapter 2: PPARα/γ Expression and Activity in
Mouse Melanocytes and Melanoma Cells_________
The information presented in this chapter is the author’s contribution to the
following manuscript “PPARα/γ Expression and Activity in Mouse and Human
Melanocytes and Melanoma Cells.”

This manuscript was accepted for

publication in Pharmaceutical Research (2008) 25:1326-1333. Reprinting for
dissertation is part of the author’s rights and permission is not required from
Springer Science Business Media, LLC.
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Abstract
The purpose of this research was to examine the expression of PPARs and the
effects of PPARα and PPARγ agonists on the growth of mouse melanocytes and
melanoma cells. Expression of PPARα, β, and γ mRNA levels in melan-a mouse
melanocytes and B16 mouse melanoma cells was assayed quantitatively by RTPCR, while quantitative PPARα mRNA levels were measured by QuantiGene
assay. The effects of natural (PGJ2, leukotriene B4) and synthetic (ciglitazone,
troglitazone, WY14643) PPAR ligands on cell growth were also examined, while
PPAR transcriptional activity was determined by a PPRE-reporter gene assay.
B16 melanoma cells produced more PPARα and PPARγ protein than melan-a
melanocytes. However, B16 PPARα mRNA levels were similar to those of
melan-a melanocytes. The PPARγ-selective agonists were able to significantly
inhibit the cell growth of both melan-a melanocytes and B16 mouse melanoma
cells, while PPARα-selective agonists had limited effects on melanoma growth.
The increased expression of PPARα and γ protein in B16 cells compared to
melan-a melanocytes may be a common occurrence in melanoma, however, its
biological significance remains to be determined. Selective PPARγ agonists may
prove useful to arrest the growth of some melanomas.

Introduction
PPARs are members of the nuclear receptor superfamily of ligand-activated
transcription factors. There are three subtypes-PPARα, PPARβ/δ, and PPARγ.
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Endogenous fatty acids and synthetic agonists activate these receptors. Upon
activation, PPARs regulate genes involved in lipid and glucose homeostasis
(Green, 1995; Eschler and Wahli, 2000; Berger and Moller, 2002).

These

receptors also regulate normal and disease related processes, including embryo
implantation,

inflammation,

cell

cycle

progression,

differentiation

and

tumorigenesis (Berger and Moller, 2002).
Activation of PPARs decreases cell growth and induces differentiation in
many cancer cell lines (Mueller, et. al., 1998; Kawa, et. al., 2002; He, et. al.,
2005). However, there is little information on the PPAR subtypes and relative
levels of PPAR expressed in melanocytes and melanoma cells (Kang, et. al.,
2004). We therefore characterized the types of PPARs, level of PPARα and
PPARγ mRNA and protein, and the ability of PPAR-selective agonists to inhibit
proliferation in mouse melanocytes and melanoma cells.

Materials and Methods
PPAR Agonists
Leukotriene B4 was obtained from Sigma Chemical Co. (St. Louis MO).
Ciglitazone, 15-Deoxy-∆12,14-prostaglandin J2 (PGJ2), and WY14643 were
obtained from Biomol Research Laboratories, Inc. (Plymouth Meeting, PA).
Troglitazone was obtained from Axxora, LLC (San Diego, CA). A stock solution
of LTB4 was made using 102 µg/ml in 100% ethanol and diluted to 0.01, 0.05 and
0.1 µM concentrations in DMEM complete media. For ciglitazone, troglitazone,
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and WY14643, 10-2M stock solutions were made using DMSO and diluted to 1, 5,
and 10 µM concentrations in DMEM complete media.

Cell Culture
B16 mouse melanoma cells were grown in Dulbecco’s Modified Eagle’s
Medium (DMEM; GIBCO/Invitrogen, Carlsbad, CA), as described previously
(Boskovic, 2004). Melan-a cells (Dr. D. Bennett, Department of Anatomy and
Developmental Biology, St. George’s Hospital Medical School, London,
England) were grown in RPMI 1640 medium as previously described (Boskovic,
2004). Cells were maintained in a 10% CO2/90% air humidified atmosphere.
Both the B16 (ATCC, Manassas, VA) and melan-a cell lines were derived from
the C57/BL6 mouse.

Western Blots and Antibodies
Equal amounts of protein (50µg) were separated using 7.5% SDS-PAGE gels
and transferred to blotting membranes. The blots were blocked with 5% non-fat
dry milk overnight at 4°C and probed with the following antibodies: monoclonal
mouse PPARα for mouse melanocytes and melanoma 1:250 (Affinity
Bioreagents, Golden CO); and polyclonal PPARγ2 1:500 (Cell Signaling
Technology, Beverly, MA). Secondary antibodies were polyclonal HRP-linked
anti-rabbit IgG (Cell Signaling Technology, Beverly, MA) and monoclonal antimouse IgG (Amersham, Chicago, IL) used at 1:3000. Blots were developed with
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ECL reagents (Amersham, Chicago, IL), and the chemiluminescent signal
quantified with a Chemi-doc Imager (Bio-Rad).

Reverse Transcriptase Polymerase Chain Reaction
Total RNA was extracted using Tri-Reagent (Sigma Chemical Co.) and
reverse transcribed using the RT for PCR kit (Clontech, Palo Alto, CA). PCR
was performed using the following primers: mouse; PPARα forward 5’AGCTGGTGTAGCAAGTGT-3’, reverse 5’-TCTGCTTTCAGTTTTGCTTT-3’
product 163 bp; PPARβ/δ forward 5’-CCCGGGAAGAGGAGAAAGAG-3’,
reverse 5’-AAAGCGGATAGCGTTGTGC-3’ product 402 bp; and PPARγ2
forward 5’-CCAGTGTGAATTACAGAAATCTCTGTTTTATGCTG-3’, reverse
5’-AGAACGTGATTTCTCAGCC-3’ product 120 bp. The PCR was performed
with the AccuPrime Taq DNA Polymerase System (Invitrogen) with the
following conditions: PPARα and PPARγ, 40 cycles of 94° C, 30 s; 65° C, 30 s;
68° C, 1minute; PPARβ/δ, 40 cycles of 94° C, 30 s; 65° C, 30 s; 68° C, 1 minute.
PCR products were electrophoresed through 1% agarose gels and visualized with
ethidium bromide.

QuantiGene Assay
RNA from cells was extracted with Tri-Reagent.

QuantiGene assays

(Panomics, Inc., Freemont, CA) were performed according to the manufacturer’s
protocol. Briefly, 2 µg of RNA in 10 µl was loaded into each well of a 96 well
plate and incubated with PPARα, β-actin target probes, in conjunction with
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dendrimer DNA amplifier and labeled probes at 56° C overnight. Following
several washes with QuantiGene buffer, chemiluminescent substrate was added to
the wells and incubated at 56° C for 30 minutes. The reaction signals (relative
light units – RLU) were measured using a Centro LB 960 luminometric plate
reader (W. Nuhsbaum Inc., McHenry, IL).

Reporter Gene Assays
B16 cells were seeded at a density of 3x105 per 60 mm tissue culture dish.
Each assay was performed in triplicate.

The mouse melanoma cells were

transfected with β-galactosidase (β-galactosidase Enzyme Assay System,
Promega Corp., Madison, WI); pGL-2x-PPRE-Luciferase reporter plasmid (Dr.
John Capone, Department of Biochemistry, McMaster University, Hamilton, ON,
Canada); pSV sport PPARα or pSV sport-PPARγ expression vectors (Dr. Bruce
Spiegelman, Dana-Farber Cancer Institute, Boston, MA). The plasmid DNA ratio
was 1:10:10 respectively. Lipofectamine plus reagent kit was used to transfect
the cells (Invitrogen). After transfection, media, serum and appropriate agonists
were added to the cells. Cells were harvested after 48h, and assayed for βgalactosidase and

luciferase

activity using

kits

from

Promega

Corp.

Chemiluminescence was determined using a Lumat LB 9501 Luminometer.
Transfection efficiency was corrected by measuring the amount of βgalactosidase activity.
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Statistics
Samples for each experiment were performed in triplicate (n=3). Biological
repeats for each experiment were performed at least three times, or more if
necessary.

Statistical significance determined using the SigmaStat analysis

program. Sample comparisons were made using One Way ANOVA (analysis of
variance).

Probability of significance was determined using the Student-

Knewman Keuls t-test. Standard error bars are shown.

Results
Expression of PPAR subtypes
The expression of PPAR subtypes in mouse melan-a melanocytes and B16
mouse melanoma cancer cells was examined using RT-PCR. Figure 2.1 shows
that mouse melanocytes and melanoma cells express mRNA for PPARα,
PPARβ/δ, and PPARγ2.
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Figure 2.1. Expression of PPAR subtype mRNA in mouse melanocytes and
melanoma cells. RNA was isolated, purified and reverse transcribed using the
Advantage RT-for PCR kit (Clontech, Palo Alto, CA).

PCR analysis was

performed using the specific primers for each subtype listed in the “Materials and
Methods”.

Because RT-PCR provides only qualitative results, we also measured the
relative amount of PPARα and PPARγ protein and PPARα mRNA in these cells
using Western blotting and QuantiGene assays respectively. Unfortunately, we
could not Quantitate PPARγ mRNA levels because there are no capture probes for
this RNA species. Results show that B16 melanoma cells expressed higher levels
of PPARα (52 kD) and PPARγ (56 kD) protein compared to non-malignant
melan-a cells (Figure 2.2). Quantitation of the immunoblots revealed that B16
mouse melanoma cells have threefold more PPARα and 40% more PPARγ
protein than melan-a mouse melanocytes (Figure 2.2A and B).
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Figure 2.2. Expression of PPAR subtype protein in mouse melanocytes and
melanoma cells.

Proteins were separated and PPARs detected by selected

antibodies as outlined in “Materials and Methods”. Relative amounts of PPARα
and PPARγ were determined by densitometry (bar diagram) and corrected for the
amount of actin in each sample. A and B represent PPARα and PPARγ protein
expression respectively in mouse melan-a melanocytes and B16 melanoma cells.
A representative analysis is shown.

The experiments were repeated three

additional times with the same qualitative results.
QuantiGene assays (Panomics) revealed that mouse B16 melanoma cells had
60% less PPARα mRNA compared to the melan-a melanocytes (Figure 2.3).
This is in stark contrast to the level of PPARα protein, which is threefold higher
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in B16 relative to melan-a cells. While there is not a strong correlation between
mRNA and protein levels for this receptor in the mouse melanoma cells, it does
suggest that the expression of PPARα it regulated at the translational level.

40% ↓

Figure 2.3. Quantitation of PPARα mRNA levels in mouse melan-a melanocytes
and B16 melanoma cells. The QuantiGene assay system was used to determine
relative amounts of PPARα mRNA. Cell lysates were loaded into wells of a
QuantiGene capture plate and hybridized to probes specific for mouse PPARα
mRNA. A representative experiment representing the ratio of PPARα expression,
corrected for β-actin is shown. This experiment was repeated twice with similar
results.
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Effect of PPARα and PPARγ Agonists on Cell Proliferation
We measured the effect of PPAR-selective agonists on melanocyte and
melanoma cell proliferation. Agonist concentrations were chosen that would
maximize receptor subtype specificity.

The natural PPARγ agonist, PGJ2,

inhibited the growth of both melan-a melanocytes and B16 melanoma cells (27%
and 33% respectively) (Figure 2.4A). The synthetic PPARγ agonist ciglitazone
also inhibited the growth of melan-a and B16 cells (33% and 22% respectively)
(Figure 2.4B), while troglitazone, a synthetic and highly selective PPARγ agonist,
was only able to inhibit the growth of B16 melanoma cells (36%) (Figure 2.4C).
The synthetic PPARα agonist, WY14643, had no significant effect on
proliferation of melan-a and B16 cells (Figure 2.4D), while the natural PPARα
agonist LTB4, inhibited the growth of the melan-a cells but not B16 cells (Figure
2.4E).
Figure 2.4A.
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Figure 2.4B.
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Figure 2.4C.
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Figure 2.4D.
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Figure 2.4E.
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Figure 2.4. Effect of PPAR agonists on mouse melan-a melanocytes and B16
melanoma cell proliferation. (A, PGJ2; B, ciglitazone; C, troglitazone; D,
WY14643; and E, LTB4) Triplicate dishes of cells were treated with the indicated
concentration of agonist for 48h (previously determined to be the most effective
treatment time), then harvested and cell number determined by cell counts with a
hemocytometer. Data are presented as cell number after 48h treatment with
appropriate agonist. The error bars represent the SEM of triplicate dishes at each
concentration of agonist tested. All experiments were repeated a minimum of
three times with similar results. (∗ = Melan-a; + = B16; significantly different
relative to control cells p<0.05)

PPAR Trans-Activation
PPAR agonists have non-receptor-mediated effects. For example, PGJ2 alters
NF-κB activity (Okano, et. al., 2003). Therefore, we compared the concentrationdependent ability of the three PPARγ agonists PGJ2, Ciglitazone, and
Troglitazone, as well as the PPARα agonist WY14643, to stimulate PPRE
reporter gene activity in B16 mouse melanoma cells and correlated this activity
with their ability to inhibit the growth of the same cell line. B16 cells were cotransfected with either the PPARγ or PPARα expression plasmid since
endogenous PPRE reporter gene activity was too low to be accurately detected.
The PPARγ agonists, PGJ2 and ciglitazone stimulated PPRE reporter gene
activity in a dose dependent manner (Figure 2.5A and B).

There was also

significant reporter gene activity when B16 cells were treated with troglitazone or
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WY14643 (Figure 2.5C and D). The ability of these agonists to stimulate the
reporter gene correlated with their ability to inhibit B16 cell proliferation (Figure
2.4). However, the amount of growth activity was small (22-36%), relative to the
increase in reporter gene activity, which ranged from 2-fold (WY), to 5-fold
(Cig).
A.

B.

C.

D.

Figure 2.5. Ability of PPAR agonists to increase PPRE reporter gene expression.
A β-galactosidase expression plasmid and a 2x PPRE pSG5-luciferase plasmid
were transiently co-transfected into B16 cells. The transfection mixture also
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contained either pSV-PPARγ (A, B, and C) or pSV-PPARα (D), with a plasmid
DNA ratio of 1:10:10 respectively. Cells were harvested and assayed for βgalactosidase and luciferase activity 48h after agonist addition. The error bars
represent the SEM of triplicate dishes of transfected cells. The experiment was
repeated three times with similar results.

(∗p<0.001) Significantly different

relative to transfected cells without agonist.

(A PGJ2; B Ciglitazone; C

Troglitazone; D WY14643).

Discussion
Aberrant expression of PPARs has been found in several types of cancers such
as colon, prostate, lung, skin, breast, and liposarcomas (Tontonoz, et. al., 1997;
Inoue, et. al., 2001; Suchanek, et. al., 2002; Segawa, et. al., 2003; Aung, et. al.,
2005; Nijsten, et. al., 2005). Overexpression of PPARα might contribute to
tumorigenesis through its ability to stimulate proliferation by enhancing
expression of genes encoding CDK-1 and CDK-4 and c-myc (Miller, et. al., 1996;
Zang, et. al., 2006). In contrast, expression and activation of PPARγ is reported
to stimulate differentiation and inhibit cell proliferation of several carcinomaderived cell lines (Mueller, et. al., 1998; Kawa, et. al., 2002; Park, et. al., 2005).
In the skin, PPARα is involved in maintaining epidermal barrier function as well
as differentiation and wound healing (Di-Poi, et. al., 2004; Michalik, et. al.,
2005). The types of PPAR expressed in normal melanocytes and whether their
expression is altered in melanoma cells has not been well studied. We found that
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all of the PPAR subtypes, including PPARβ/δ are expressed at the mRNA level
by mouse melanocytes and melanoma cells. Quantitative assay of mRNA levels
revealed that melan-a melanocytes had more PPARα mRNA than B16 melanoma
cells. In contrast, B16 cells had much higher amounts of PPARα protein relative
to melan-a melanocytes. These findings suggest there is significant regulation of
PPARα at the protein level, possibly through efficiency of translation.

The

amount of PPARγ was also higher in B16 melanoma cells. Unfortunately, due to
a lack of a PPARγ capture probe for the QuantiGene assay, we could not
quantitatively compare the mRNA and protein levels for this PPAR subtype to see
whether it also might be subjected to regulation at the protein level.
Several groups have reported that PPARγ-selective ligands can inhibit the
growth of human melanoma cells (Plachaa, et. al., 2003; Freudlsperger, et. al.,
2006; Lee, et. al., 2007).

However, in several of these reports, significant

inhibition of proliferation did not occur until 20 µM or higher concentrations of
ligand. Many natural and synthetic PPAR ligands lose their selectivity at these
concentrations (Selmandi, et. al., 2005).

We therefore limited our ligand

concentrations to a maximum of 10 µM. While the effects on cell growth were
significant, the compounds were only moderately effective at inhibiting
proliferation using this concentration.
It is curious that B16 mouse melanoma cells express high levels of both
PPARα and γ relative to their non-transformed counterpart, melan-a melanocytes,
yet are either not growth inhibited by receptor-selective ligands or their inhibition
is similar to normal melanocytes. One possible reason for this may be due to

- 50 -

changes in expression or activity of PGC-1α (PPARγ Co-activator 1α). This
cofactor is involved in regulating the activity and binding specificity of PPAR
receptors to their response elements. This process is important for activation of
specific target genes. The reduction of PGC-1α expression has been implicated in
type II diabetes; however, I found very little information on PGC-1α expression
and activity in melanoma.
Because it has been reported that PPAR ligands can have receptor-independent
effects (Okano, et. al., 2003; Chaffer, et. al., 2006), we compared their
concentration-dependent ability to activate PPRE reporter gene activity with their
concentration-dependent ability to inhibit the growth of B16 mouse melanoma
cells. In general, we found a good correlation between these two activities in B16
cells. However, the degree of growth inhibition did not correlate as well with the
level of gene activity. For the reporter gene assays, we co-transfected plasmids
encoding the PPARγ and PPARα proteins into the B16 cells, since it was difficult
to detect endogenous ligand-activated reporter gene activity. Therefore, it is
possible that the endogenous PPARα and γ receptors in the B16 melanoma cells
are defect in transcriptional activation despite being over-expressed relative to
normal melan-a melanocytes. One reason for this may be due to the constitutive
activation of the MAPK pathway. The B16 cells contain an NRAS mutation that
drives the activation of ERK1/2. The phosphorylation of specific serines in the
N-terminal region, regulate the activity of the receptors in a ligand-independent
manner.

This leads to a change in its conformation and a decrease in its

transcriptional activity.
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Conclusion
In summary, we have found that mouse melan-a melanocytes and B16
melanoma cells express PPARα, PPARβ/δ, and PPARγ2 receptors.

The

melanoma cells overexpress PPARα and PPARγ protein relative to melanocytes,
however, there is a discordance between RNA and protein levels for these
receptors. The ability of PPAR ligands, at concentrations where selectivity was
maintained, to inhibit replication of these cells was variable and did not correlate
as well with the expression level of the relevant PPAR.

We did not find

convincing evidence that PPARs are involved in development or maintenance of
the melanoma phenotype as there was no observable change in their physical
characteristics.

However, PPARγ ligands at pharmacological concentrations

might be useful in the treatment of certain melanoma lesions (Liu, et. al., 2006).
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Rationale for Discontinuing PPAR Project and
Initiating a New Project Involving Retinoic Acid
and AKAP12________________________________
Data I acquired in the PPAR part of my thesis work were published together
with data obtained by co-author Dr. Caroline Mills and her work with PPARs in
human melanoma cells.
To ascertain the effect of PPARα down-regulation on melanoma cell biology,
Dr. Mills transfected SK-mel28 human melanoma cells with siRNA to PPARα in
order to down-regulate the expression of this gene. Even though QuantiGene
assays determined that there was >80% knockdown of PPARα after 96 hours
after transfection, there was no change in any biological parameter that was
measured. Cell growth, morphology and viability of SK-mel28 melanoma cells
were examined in these cells and no changes in the cell phenotype were observed.
In addition, a known transcriptional target of PPARα, medium chain acyl CoA
dehydrogenase (MCAD) protein was measured by Western blotting to determine
whether PPARα knockdown decreased the amount of this protein. There was no
change in MCAD protein levels between SK-mel28 cells transfected with PPARα
siRNA or control siRNA, which could be because there was not a complete
knockdown of protein expression. The amount of remaining protein would still
be able to activate gene transcription.

Also, these receptors have redundant

functions; therefore, the PPARβ/δ or γ proteins may act as a substitute for
PPARα. Due to the inability of PPARα downregulation to induce changes in the
melanoma phenotype, we decided to end this project and search for another
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avenue of research that might lead to an understanding of how retinoids can cause
growth arrest and differentiation in responsive melanoma cells.
During this same time frame, our laboratory was using microarrays for gene
expression profiling to determine the effect of atRA treatment on B16 melanoma
gene expression. The results of the microarray analysis showed that after 48
hours of atRA treatment, there was one gene, AKAP12 whose expression was
increased 28 fold relative to control cells. A thorough literature search did not
yield any publications describing this gene or its regulation in melanocytes or
melanoma cells. Therefore, with the permission and encouragement of my thesis
advisor, Dr. Richard Niles, I initiated a study of the expression, atRA regulation
and possible role of AKAP12 in melanoma.
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Chapter 3: Retinoic Acid Regulated AKAP12
Expression in Mouse and Human Melanocytes and
Melanoma Cells______________________________
Abstract
Retinoic Acid (atRA) is the most biologically active form of Vitamin A and
inhibits the growth of mouse and human melanoma cells. Profiling of atRA
regulated genes in B16 melanoma identified AKAP12, a scaffolding protein
involved in assembling multi-protein signaling complexes, as the most highly
induced gene at 48 h of atRA treatment. In this chapter I report that atRA also
regulates AKAP12 expression in human melanocytes and melanoma cells and
provide evidence for the involvement of AP-1 in the regulation of AKAP12 gene
expression.

Functional studies involving knockdown of AKAP12 expression

using siRNA showed that AKAP12 was involved in the regulation of invasive and
anchorage-independent growth properties. The basal mRNA and protein levels of
AKAP12 differed among human melanocytes and six human melanoma cell lines.
Also, AKAP12 mRNA and protein was differentially induced by atRA in the
different human melanoma cell lines. There was a significant correlation between
atRA induced increases in AKAP12 levels among the melanoma cell lines and the
ability of atRA to inhibit proliferation.

In silico analysis of the AKAP12

promoter region revealed 3 activator protein (AP-1) transcription factor binding
sites. Since atRA stimulates AP-1 activity in B16 melanoma cells (Desai and
Niles, 1997; Huang, et. al., 2002), I examined whether AP-1 mediated the atRA
induction of AKAP12.

Reporter gene assays showed that atRA treatment
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increased AP-1 activity in WM3248 and WM239 human melanoma cells. Cotransfection of these melanoma cells with an AP-1 reporter plasmid and a
dominant-negative c-fos (A-fos) resulted in inhibition of atRA induced AP-1
activity. Unexpectedly, transfection of the A-fos plasmid into human melanoma
cells enhanced rather than inhibited atRA induced AKAP12 expression. These
data suggest that rather than mediating the stimulation of AKAP12 expression by
atRA, AP-1 attenuates the induction of this gene.

Introduction
The most aggressive form of skin cancer is cutaneous malignant melanoma
(CMM). Although it accounts for only 4% of all skin cancers, it is responsible for
nearly 80% of the total number of skin cancer related deaths in the United States.
The incidence of melanoma is steadily growing, becoming one of the fastest
growing cancers worldwide (Boyle, 2011; www.cancer.org).

Melanoma

progression undergoes distinct phases (Urso, 2004; Melinkova and Bar-Eli, 2008).
In the radial growth phase (RGP), the cancer cells spread horizontally and are
confined to the epidermis. If detected during this phase of development surgical
excision leads to a very high cure rate. In the vertical growth phase (VGP), the
melanoma cells penetrate vertically through the basement membrane and invade
the dermis and underlying tissues. The metastatic phase (Met) is characterized by
the ability of melanoma cells to spread to distant organs and at this stage the
disease is usually incurable. Melanoma is among the most aggressive tumor types
because of its high capacity to metastasize and its resistance to treatment.
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Currently, there are few effective therapies available for the treatment of
metastatic melanoma (Lens, 2008; Boyle, 2011).
Retinoids are natural or synthetic derivatives of Vitamin A. All-trans retinoic
acid (atRA) is the active metabolite of Vitamin A and inhibits growth and/or
induces differentiation in a variety of tumors (Nettesheim, 1980; Garattini, et. al.,
2008), including mouse and human melanoma (Fliegel, et. al., 1992; Desai, et. al.,
2000; Niles, 2003). Our laboratory studies the mechanism by which atRA exerts
its biological effects in melanoma cells. Gene expression profiling during a 4-48
hour treatment of B16 mouse melanoma cells with atRA identified the gene
coding for A-Kinase Anchoring Protein 12 (AKAP12) as the highest induced
gene at the 48 hour time point.
AKAP12, also known as AKAP250 or Gravin, is a member of a family of
structurally diverse but functionally similar scaffolding proteins. These proteins
are involved in assembling multi-protein signaling complexes that function to
promote efficient and specific enzyme/substrate reactions in a spatial and
temporal manner (Gelman, 2002).

The hAKAP12 gene is located on

chromosome 6q24-25.2, which has been found to be a deletion hotspot in
advanced prostate, breast and ovarian cancer, and may encode one or more tumor
suppressor genes (Cooney, et. al., 1996; Noviello, et. al., 1996; Tibiletti, et. al.,
2000; Tibiletti, et. al., 2001; Gelman, 2002; Abdollahi, et. al., 2003; Gorringe, et.
al., 2009).
The objective for this study was to determine whether atRA also stimulated
AKAP12 protein and RNA expression in human melanocytes and a series of
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human melanoma cell lines established from different stages of malignant
progression. I also examined the possible intermediary role of RA-induced AP-1
activity on AKAP12 gene regulation. AKAP12 was differentially expressed and
induced by atRA in melanocytes and in six different melanoma cell lines. There
was a significant correlation between atRA’s ability to induce AKAP12
expression and its ability to inhibit growth.

Unexpectedly, AP-1 was

demonstrated to be a negative regulator of AKAP12 mRNA expression. Downregulation of AKAP12 expression in mouse and human melanoma cells led to an
increase in invasiveness and an increased ability to grow in an anchorageindependent manner.

Materials and Methods
Cell Culture
Samples of human epidermal neonatal lightly pigmented melanocytes (HEMnLP) were obtained from Cascade Biologics, Portland, OR, and maintained in
Medium 254 supplemented with 5 ml human melanocyte growth serum (HMGS)
and 1 ml penicillin, streptomycin and amphotericin B (PSA) solution per 500 ml
bottle.

SbCl2 and WM3211 cells were isolated from radial growth phase

melanomas, WM1366 and WM3248 were isolated from vertical growth phase
melanomas, and WM9 and WM239 cells were isolated from metastatic
melanomas. These cell lines were obtained from Meenhard Herlyn, D.V.M.,
D.Sc., Professor and Director of the Molecular and Cellular Oncogenesis Program
at The Wistar Institute, Philadelphia, PA. Cells were grown as described (Mills,
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et. al., 2009). The B16 mouse melanoma cells (ATCC, Manassas, VA) were
grown in RPMI 1640 media (Gibco/Invitrogen, Carlsbad, CA) with 10% FBS and
1% pen/strep. All cells were maintained at 37º in cell culture incubators with a
5% CO2/95% air humidified atmosphere.

Retinoic Acid
All-trans retinoic acid was purchased from Sigma Chemical Co. (St. Louis, MO).
All experiments involving the use of RA were conducted under yellow light to
prevent photo-oxidation of this retinoid. A 10 mM stock solution was prepared in
DMSO. Control cells received the same volume of vehicle. Stock solution was
diluted to the desired final concentration in tissue culture medium.

RNA Extraction and DNA Microarray Analysis
Control and 10 µM atRA treated B16 cells were harvested at 4, 10, 24, and 48
hours after treatment. RNA was extracted using TRI Reagent (Sigma Chemical
Co., St. Louis, MO) according to the manufacturer’s suggested protocol.
Microarray gene profiling was performed as previously described (Estler, et. al.,
2008). The calculated log ratios were compared for significant deviation from
zero using one-class Significance Analysis of Microarrays (SAM) (Tusher, et. al.,
2001). SAM was performed with the maximum number of unique permutations
available. Delta values were chosen to give a median False Discovery Rate of
10%. This setting allowed for the detection of RARβ expression, which is used as
a control and is a direct target gene of RA.
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QuantiGene Analysis
RNA from control and 10 µM atRA stimulated B16 cells was extracted using TRI
Reagent (Sigma Chemical Co., St. Louis, MO).

QuantiGene assays were

performed according to the manufacturer’s protocol. Briefly, 2 µg/10 µl RNA
was loaded into each well of the 96 well plate and incubated overnight at 56° C
with AKAP12 and β-actin target probes, in conjunction with dendrimer DNA
amplifier.

Following several washes with supplied buffer, chemiluminescent

substrate was added to the wells and the plates incubated at 56° C for 30 minutes,
and luminescence measured on a Centro LB 960 luminometric plate reader (W.
Nuhsbaum Inc., McHenry, IL).

Western Blot Analysis
HEMn-LP, SbCl2, WM3211, WM3248, WM1366, WM239, and WM9 cells were
treated +/- 10 µM atRA for 48 hours and harvested in lysis buffer containing
Complete Mini Protease Inhibitor (Roche Diagnostics, Mannheim, Germany).
Protein concentration was measured with a Nanodrop spectrophotometer
(Nanodrop Technologies, Wilmington, DE) and 30 µg of total cellular protein
from control and treated cells was separated on 5% gels and transferred to
nitrocellulose membranes.

Membranes were blocked with 5% BSA at 4° C

overnight and then probed with the pAKAP12 antibody (1:500) (AbCam,
Cambridge, MA) at 4° C overnight, followed by an incubation with HRP-linked
anti-goat IgG (1:1000) (Vector Laboratories, Burlington, CA) for 1 hour at room
temperature.

Since this antibody was discontinued, Western blot analysis of
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protein levels after siRNA transfection used a new pAKAP12 antibody (1:1000)
(Novus Biologicals), followed by an incubation with HRP-linked anti-rabbit IgG
(1:1000) (Cell Signaling). The membranes were stripped using Re-Blot Plus
antibody stripping solution (Chemicon International, Temecula, CA). Next, the
membranes were incubated with polyclonal β-Catenin antibody (1:500) (Sigma
Chemical Co., St. Louis, MO) at 4°C overnight, followed by an incubation with
HRP-linked anti-rabbit IgG (1:500) (Cell Signaling Technology, Beverly, MA).
Blots were developed with ECL reagent (Amersham, Chicago, IL) and the
chemiluminescent signal was quantified using a Chemi-Doc Imager (Bio-Rad).
Protein loading was normalized using β-catenin expression. The use of 5% gels
only retains proteins that have a molecular weight of approximately 70kD or
higher. Most conventional proteins used to control for protein loading are lower
than 70kD and therefore not appropriate for this type of gel. Levels of β-catenin
protein expression are similar in each of the cell lines used and determined to be a
good housekeeping protein for these Western Blots.

Quantitative RT-PCR
HEMn-LP, SbCl2, WM3211, WM3248, WM1366, WM239, and WM9 cells were
treated with +/- 10µM atRA for 48 hours. RNA was extracted using the RNeasy
Mini kit (#74104, Qiagen, Valencia, CA). Purified RNA samples were dissolved
in RNase–free water and quantified using a Nanodrop Spectrophotometer
(Nanodrop Technology Inc., Wilmington, DE). Each sample had a 260/280 ratio
of greater than or equal to 1.8. RNA quality was assessed by electrophoretic
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analysis on an Agilent Model 2100 Bioanalyzer (Santa Clara, CA). All RNA
samples used had RNA Integrity Numbers greater than 9. RNA was reverse
transcribed to cDNA using an RT-for-PCR kit (Clontech, Palo Alto, CA) and
random hexamer primers. QPCR analysis was performed using ABI TaqMan
probes for human or mouse isoforms of AKAP12 and an 18S probe was used as a
control. Assays were performed under conditions specified in the ABI TaqMan
Gene Quantitation assay protocol. For functional assays using siRNA, RNA was
isolated 96 and 120 hours after transfection using the method stated above. Data
is expressed as ∆∆CT and normalized for 18S expression. This method (∆∆CT) is
used to measure relative changes in gene expression of a sample compared to that
of a control. Experiments were repeated a minimum of three times.

Plasmid DNA Constructs
The pGL2-4X-AP-1 –luciferase reporter plasmid was constructed as previously
described (Desai and Niles, 1997). The pCMV500 A-fos plasmid was kindly
provided by Dr. Charles Vinson at the National Cancer Institute.

Transient Transfections and Reporter Gene Assays
B16 cells were seeded at a density of 1.5x105, while WM3248 and WM239 cells
were seeded at a density of 3x105 in 60 mm tissue culture dishes. Two groups of
three plates each were co-transfected with the β-galactosidase (Promega Corp.,
Madison, WI) and the AP-1 luciferase reporter plasmids, while an additional two
groups of three plates each were co-transfected with the β-galactosidase, AP-1
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reporter and A-fos plasmids. Fugene 6 Transfection Reagent (Roche Diagnostics,
Indianapolis, IN) was used to transfect cells at a ratio of 1:3, Fugene 6 to µg of
DNA. After 5 hours of incubation with the transfection mixture, the media was
changed to the regular growth media and the next morning 10 µM atRA was
added to appropriate plates.

Cells were harvested after 48 hours of atRA

treatment and β-galactosidase and luciferase activity assayed (Promega Corp.,
Madison, WI).

Chemiluminescence was measured using a Lumat LB 9501

Luminometer and corrected for transfection efficiency as estimated by β-gal
activity.

siRNA Transfection
AKAP12 expression was knocked down by treating cells with siRNA directed
against AKAP12. WM3248 and B16 cells were seeded at 3.5x105 and 1.5x105
respectively into 60 mm tissue culture dishes. After 24 hours, the medium was
changed to 1.6 ml RPMI 1640 complete (seeding medium). The transfection
solution consisted of 800 µl ECR buffer with 50nM siGLO transfection indicator,
and either 50nM control siRNA or 50 nM AKAP12 siRNA. This mixture was
incubated for 5 minutes at room temperature (RT). Next, 30 µl of RNAifect
reagent was added to the mixture and incubated for an additional 15 minutes at
RT.

Lastly, 400 µl of the transfection mixture was added to each of the

appropriate dishes and cells were incubated overnight. The following morning
the medium was changed to 4 ml RPMI 1640. Control siRNA (siGenome Nontargeting siRNA #1), mouse and human AKAP12 siRNA, and siGLO green
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transfection reagents were purchased from Dharmacon/ThermoScientific,
Lafayette, CO. RNAifect reagents were purchased from Qiagen (Valencia, CA).

Cell Invasion Assay
Cytoselect 24-well Cell Invasion Assay kit was purchased from Cell Biolabs,
Inc., San Diego, CA. A suspension containing 5x105 cells/ml in serum-free RPMI
1640 media was used for WM3248 (human) and B16 (mouse) melanoma cells.
For B16 cells, the medium also contained 30 mg/ml serum albumin and, when
appropriate, 1x10-7M atRA. Inserts containing the dried basement membrane
matrix were placed in appropriate wells of the plate and rehydrated with 300 µl of
serum-free RPMI 1640 media for 1 hour at RT. Next, the rehydration medium
was removed and 500 µl of RPMI 1640 containing 10% FBS as a chemoattractant was added to the lower chamber and 300 µl (1.66x105) of cells were
added to the upper chamber. For B16 cells, control samples contained 30 mg/ml
serum albumin, while test samples contained 30mg/ml albumin and 1x10-7M
atRA. Cells were incubated at 37° C for 48 hours. To harvest invasive cells, noninvasive cells were first removed from the top of the insert with a cotton swab.
The inserts were then stained with cell stain dye solution for 10 minutes, washed,
air dried and photographed (Olympus DP12 digital microscope camera system,
Melville NY). Next, the stained cells were solubilized with 200 µl extraction
solution, and 100 µl from each sample transferred to a 96 well plate and OD
measured at 560nM (Molecular Devices, Vmax kinetic microplate reader).
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Anchorage-Independent Growth Assay
CytoSelect 96-well Cell Transformation Assay (Soft Agar Colony Formation)
kit was purchased from Cell Biolabs, Inc., San Diego, CA. For the first layer of
agar, a 1.2% agar solution was produced and solubilized using a microwave on
high for 1 minute 15 seconds and allowed to cool in a 37° C water bath. The,
2xDMEM/20% FBS media was also warmed to 37° C in a water bath. Equal
volumes of these solutions were mixed (1:1) and 50µl of this mixture was added
to each sample well of a sterile, 96-well, flat-bottomed, black microplate. The
plate was then transferred to 4°C for 30 minutes to allow the base layer to
solidify. For the second layer, cells were harvested and resuspended at 4x105 in
RPMI 1640 media. Control samples contained a similar volume of DMSO while
test samples contained 3x10-7M atRA. Cell suspensions were mixed 1:1:1 with
1.2% agar and 2xDMEM/20% FBS media. The final concentration of atRA was
1x10-7M.

Control or atRA treated cells (10,000 cells/75 µl) were added to

appropriate wells already containing the base agar layer. The microwell plate was
transferred to 4° C for 15 minutes to solidify the top agar layer. Last, 100 ul of
RPMI 1640 complete plus 10% FBS with either DMSO (Control) or 1x10-7M
atRA was added to the appropriate wells. The 96-well plate was incubated for
either 48 or 72 hours at 37° C and 5% CO2.

Cells were examined and

photographed under an Olympus DP12 digital microscope camera system. The
agar was solubilized and the cells lysed and combined to ensure a homogeneous
mixture. A 10 µl sample from each well was transferred to a black, 96 well plate
for fluorescence measurement. Just before use, the CyQuant working solution
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was made by diluting CyQuant CR Dye 1:400 with 1X PBS. A 90 µl aliquot of
CyQuant working solution was added to each well. The plates were immediately
wrapped in foil and kept under low lighting conditions during a 10 minute
incubation at room temperature.

Fluorescence was measured using a

SpectraMAX GeminiEM fluorometer with a 485/538 nm filter set. Fluorescence
is proportional to the amount of DNA present in the cells.

Statistics
Samples for each experiment were performed in triplicate (n=3). Biological
repeats for each experiment were performed at least three times, or more if
necessary.

Statistical significance determined using the SigmaStat analysis

program. Sample comparisons were made using One Way ANOVA (analysis of
variance).

Probability of significance was determined using the Student-

Knewman Keuls t-test. Standard error bars are shown.

Linear Regression Analysis
Linear regression analysis attempts to examine and model the relationship
between two or more variables using a straight line.

A GraphPad Prism 5

program was used to analyze data for this comparison. The effect of atRA on
AKAP12 mRNA expression (x) was compared to RA’s ability to inhibit growth
(y) and analyzed for statistical significance.
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Results
Microarray analysis identifies AKAP12 as an atRA induced gene
In a previous study (Estler, et. al., 2008) we used gene expression profiling to
identify genes in B16 melanoma cells whose expression is altered as a function of
different times of atRA exposure. The goal was to understand how a series of
activated/repressed genes might contribute to the ability of atRA to inhibit
proliferation and stimulate differentiation of this cell line.

This microarray

analysis showed that AKAP12 expression is induced 25.6 fold (Table 3.1) in B16
cells treated with atRA for 48 hours. AKAP12’s degree of induction was the
highest among the 717 genes whose expression was significantly increased by
atRA at this time point. To verify these microarray results, QuantaGene analysis
was performed on RNA extracted from B16 melanoma cells treated for 24, 48 and
72 hours with 10 µM atRA. Retinoic acid induced a 6-fold and a 9-fold increase
in AKAP12 mRNA at 48 and 72 hours respectively (Figure 3.2).

Table 3.1. Identification of AKAP12 as an atRA induced gene.
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Table 3.1. Gene expression profiling was performed on control and 10 µM atRA
treated B16 mouse melanoma cells (Estler, et. al., 2008). Microarray analysis
identified AKAP12 as the highest induced gene at 48 hours of atRA treatment.
The expression of AKAP12, as well as the control gene RARβ2, is shown after 4,
10, 24, and 48 hours of RA treatment.

Pathway analysis of microarray data
Data from the microarray were analyzed by the Pathway Studio v5.0 (Ariadne
Genomics) program to identify and illustrate molecular connections between
certain proteins encoded by the genes whose expression was significantly
increased by atRA. This program searches through the ResNet database for all
known interactions between genes/proteins, which includes physical interactions,
regulation of expression and protein modification, and expresses the result in
graphical form (Figure 3.1). Four major hubs for connectivity were identified.
These were cell division cycle 2 protein (CDC2), checkpoint kinase 1 (CHEK1),
CDC45 cell division cycle 45-like (CDC45L) and minichromosome maintenance
deficient protein 6 (MCM6). There were also three additional hubs that were
identified which had relatively high numbers of interactions as well. These were
p53

protein

(TP53),

cyclin-dependent

kinase

inhibitor

(CDKN1A/p21/WAF1/CIP1) and cMYC (Estler, et. al., 2008).
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Figure 3.1 Pathway Studio Analysis of Microarray Gene Set. Protein hubs that
have the most significant interactions (CDC2, CHEK1, CDC45L and MCM6) are
marked with an asterisk (∗). Although there are relatively large interactions
stemming from TP53, p21 and cMYC, these proteins were not among the most
statistically significant hubs. Green color indicates a gene is upregulated whereas
red color indicates that a gene is downregulated. Color intensity reflects the
expression ratio.

AKAP12 mRNA Expression in RA Treated B16 Cells
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Figure 3.2. Quantification of AKAP12 mRNA in B16 Mouse Melanoma Cells.
Amount of AKAP12 mRNA expression in B16 cells treated +/- 10µM atRA. The
QuantaGene Assay system was used to determine relative amounts of AKAP12
mRNA. Cell lysates were loaded into 96 well capture plates and hybridized to a
probe specific for mouse AKAP12 mRNA. Relative light units were measured on
a luminometer. The amount of AKAP12 mRNA expression, corrected for β- 73 -

actin, is shown. {(AKAP12 untreated/β-actin)/(AKAP12 + RA/β-actin + RA)}.
This experiment was repeated twice with similar results.

AKAP12 Protein and mRNA Expression after atRA Stimulation
To establish if AKAP12 expression is also regulated by atRA in human
melanocytes and melanoma cells, I examined the level of AKAP12 mRNA and
protein from control and atRA treated normal human melanocytes (HEMn-LP),
and the human melanoma cell lines SbCl2 & WM3211 (RGP); WM1366 &
WM3248 (VGP); and WM239 & WM9 (Met). These melanoma cell lines were
chosen because they were established from tumors representing different stages of
malignant progression.
All cell lines expressed AKAP12 protein and its expression was differentially
induced after atRA treatment (Figure 3.3A). The major isotype of AKAP12 in
these cells is a 305/287kD doublet, with the top band designated as the α isoform
and the lower band the β isoform (Gelman, 2002; Streb, et. al., 2004).

In

untreated HEMn-LP, WM3211 and WM3248 cells, AKAP12α was the main
isotype while untreated WM9 and WM1366 cells expressed equal amounts of the
α and β isoforms. Treatment of these cells with atRA for 48h induced expression
of both isoforms, except in SbCl2 cells where the predominant isoform was
AKAP12β. Quantification of the protein expression revealed the following order
of AKAP12 induction: SbCl2 (RGP) (3.54 fold), HEMn-LP human melanocytes
(3.38 fold), WM3248 (VGP) (2.72 fold), WM239 (Met) (2.4 fold), WM3211
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(RGP) (2.29 fold), WM9 (Met) (2.09 fold) and WM1366 (VGP) (0.9 fold) (Figure
3.3B).

Figure 3.3A

Figure 3.3B
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Figure 3.3. AKAP12 Protein Expression in Human Melanocytes and Melanoma
Cells. The amount of AKAP12 protein in control (C) and 10 µM atRA treated
(R) cells was determined by immunoblotting as described in Materials and
Methods. (A) Immunoblot of AKAP12 protein levels in SbCl2 (RGP), WM1366
(VGP), and WM9 (Met) human melanoma cells compared to HEMn-LP human
melanocytes.

Immunoblot of AKAP12 protein levels in WM3211 (RGP),

WM3248 (VGP), and WM239 (Met) human melanoma cells compared to HEMnLP human melanocytes. (B) Densitometry of immunoblots (A&B) showing the
relative changes in AKAP12 protein expression in human melanocytes and
melanoma cells after 48 hours of atRA treatment. A value of 1.0 corresponds to
the level of AKAP12 protein in control cells. These experiments were repeated
two additional times with similar results.

QRT-PCR was used to measure the amount of AKAP12 mRNA in human
melanocytes and melanoma cells treated +/- 10 µM atRA for 48 hours. All cell
lines expressed AKAP12 mRNA and its level was significantly increased relative
to control in all cell lines after atRA treatment except for WM1366 (Figure 3.4A).
There was a strong correlation between the degree of atRA induction of AKAP12
mRNA and protein expression in these cell lines. Only one cell line (WM3248VGP) had basal levels of AKAP12 mRNA that were higher than human
melanocytes.

The remaining cell lines have the same or significantly lower

amounts of AKAP12 mRNA relative to normal human melanocytes (Figure
3.4B).
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Figure 3.4A
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Figure 3.4.

atRA Stimulation of AKAP12 mRNA Expression in Human

Melanocytes and Melanoma Cells.

QRT-PCR was performed on total RNA

extracted from each of the cell lines after 48 hours of +/- 10µM atRA treatment.
(A) Changes in AKAP12 expression after atRA treatment. Data are expressed as
fold change relative to control cells and normalized using 18S ribosomal RNA
expression. (B) Basal level AKAP12 expression. Data are expressed as amount
of AKAP12 mRNA relative to HEMn-LP cells. Results are the average of 4
separate experiments. (∗ = p <0.05, • = p <0.001 compared to control)

Effect of atRA on melanoma cell growth and correlation with
induction of AKAP12 expression
Our laboratory has previously found that atRA inhibits the proliferation of
mouse and human melanoma cells (Desai and Niles 1997; Huang, et. al., 2002;
Niles, 2003; Estler, et. al., 2008; Fan, et., al., 2010). A 72 hour atRA treatment of
the human melanocyte and melanoma cell lines caused varying amounts of
inhibition of their proliferation (Table 3.2). SbCl2 (RGP) cells were the most
sensitive with a 70% decrease in cell number. SbCl2 (RGP), HEMn-LP human
melanocytes, WM3211 (RGP) and WM3248 (VGP) cell proliferation was
significantly inhibited by atRA. WM1366 (VGP), WM9 (Met) and WM239
(Met) melanoma cell proliferation was not significantly inhibited.
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Table 3.2. Effect of 72 hours of atRA Treatment on the Proliferation of Human
Melanocytes and Melanoma Cells. Cells were seeded, and after a 24 hour growth
period the media was changed. Medium contained either DMSO (control) or 10
µM atRA. Triplicate dishes from each treatment group were harvested after 24,
48 and 72 hours of treatment and the number of cells determined by
hemocytometer counts. Data are expressed as percent decrease in cell number
%

compared to control for each cell line 72 hours after treatment. ( = significantly
different from control; p<0.05)
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Linear regression analysis revealed that there was a significant correlation
(p<0.05) between the ability of atRA to inhibit proliferation and its ability to
increase AKAP12 mRNA levels (Figure 3.5).

Percent of Growth Inhibition

Slope = 13.65 / p = 0.0415 / r2 = 0.5975
100
80
60
40
20
0
0

2

4

6

AKAP12 mRNA Expression

Figure 3.5. Linear Regression Analysis of atRA Induced Increase for AKAP12
mRNA Expression and its Ability to Inhibit Proliferation of the Human
Melanocyte and Melanoma Cell Lines.

Changes in mRNA expression were

determined by QRT-PCR and compared to the ability of atRA to inhibit
proliferation of human melanocytes and melanoma cells. Data were analyzed
using the Prism 5 software program. Analysis shows a statistically significant
correlation between atRA’s ability to induce AKAP12 expression and its ability to
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inhibit proliferation, with a slope of 13.65, a p value of 0.0415 and an r2 of
0.5975.

Induction of AP-1 activity by atRA
To understand how AKAP12 gene expression is regulated by atRA we
conducted an in silico analysis of the AKAP12α promoter region in order to
identify putative transcription factor binding sites. This analysis searches highly
correlated sequence fragments versus TFMATRIX transcription factor binding
site database by Wingender E, Knueppel R, Dietze P, and Karas H
(www.cbrc.jp/htbin/nph-tfsearch). Threshold was set at 85%. We found three
putative Activator Protein 1 (AP-1) sites located at positions -3305 (AGCTCA), 4558 (GAGTCA) and -4879 (AGTTCG) upstream of the AKAP12α start site.
Previous research in our laboratory has shown that atRA treatment in B16 cells
induces a slow but sustained increase in AP-1 transcriptional activity (Desai and
Niles, 1997; Huang, et. al., 2002). Therefore, it was hypothesized that AP-1 may
be involved in mediating the atRA induction of AKAP12 gene expression.
Treatment of B16 mouse melanoma cells, WM3248 (VGP) and WM239 (Met)
human melanoma cells containing an AP-1 reporter gene with atRA resulted in a
significant increase in reporter gene activity relative to control treated cells
(Figure 3.6). The effect of atRA on AP-1 activity was specific, since adding a
dominant negative c-fos plasmid (A-fos) to the transfection mixture attenuated
both basal and atRA stimulated AP-1 activity in all the cell lines (Figure 3.6,
columns 3&4, 7&8, 11&12).
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Figure 3.6. AP-1 Activity in A-fos Transfected and atRA Treated Melanoma
Cells. Luciferase activity was measured in cell lysates that were harvested from
control and atRA treated B16, WM3248 and WM239 melanoma cells that were
co-transfected with the β-Gal, AP-1 luciferase vector and either the pCMV
control vector (columns 1, 2, 5, 6, 9, 10) or the dominant negative c-fos (A-fos)
vector (columns 3, 4, 7, 8, 11, 12). Cells were treated for 48 hours with 10 µM
atRA. Data is expressed as relative amount of luciferase activity compared to
control. Results are the average of 3 separate experiments. (∗ = p <0.05, • = p
<0.001 compared to control)

Inhibition of AP-1 activity by the dominant-negative A-fos causes
a further increase in AKAP12 expression
Having shown that the AKAP12 promoter has putative AP-1 binding sites and
that atRA stimulates AP-1 activity in both mouse and human melanoma cells, we
tested whether the dominant-negative A-fos would antagonize atRA induction of
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AKAP12 mRNA levels (Figure 3.7). Contrary to expectations, A-fos antagonism
of AP-1 activity enhanced the ability of atRA to increase AKAP12 mRNA levels.
In A-Fos transfected B16 cells, AKAP12 expression increased from nearly 29
fold to over 45 fold (an additional 55%).

A-fos expression increased atRA

stimulated AKAP12 mRNA levels from 6.5 fold to 9 fold (an additional 38%) in
WM3248 cells, and an additional 43% in WM239 cells. (Figure 3.7). These data

AKAP12 mRNA Expression in A-fos Transfected B16, WM3248 and
WM239 Melanoma Cells Treated with 10um atRA
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suggest that AP-1 is a negative regulator of AKAP12 mRNA expression.

Figure 3.7. AKAP12 mRNA Expression Levels After Down-regulation of AP-1
Activity. QRT-PCR was performed on total RNA extracted from Control and
atRA treated B16, WM3248 and WM239 melanoma cells that were transfected
with either pCMV control vector (columns 1, 2, 5, 6, 9, 10) or the A-fos plasmid
(columns 3, 4, 7, 8, 11, 12). Cells were treated for 48h with 10 µM atRA. Data is
expressed as fold change relative to control cells and normalized using 18S
ribosomal RNA expression. Results are the average of four separate experiments.
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(∗ = p <0.05, • = p <0.001 compared to control)

Statistical analysis was

performed comparing columns 2&4, 6&8, and 10&12; however, they were not
statistically significant, most likely due to the variation between the four
experiments.

Effect of AKAP12 downregulation on invasion in WM3248
(human) and B16 (mouse) melanoma cells.
To determine the effect of AKAP12 down-regulation on WM3248 and B16
melanoma cell biology, cells were transfected with siRNA to AKAP12 and
analyzed using CytoSelect Invasion Assay. These cell lines were used because
of their high induction of AKAP12 expression after atRA treatment. Initially, I
established the amount of AKAP12 RNA and protein down-regulation after
siRNA transfection in these cell lines. At 96 hours of transfection with control
siRNA and AKAP12 siRNA, total RNA and protein was isolated and AKAP12
levels examined by QRT-PCR and Western blotting. Figure 3.8 A&B shows that
in WM3248 cells treated with AKAP12 siRNA there was a 76% decrease in
mRNA and a 44% decrease in protein expression relative to cells treated with
control siRNA. In B16 cells (Figure 3.8 C&D), atRA (1x10-7M) induced a 4.7fold increase in AKAP12 mRNA and a 98% increase in protein expression in
control siRNA transfected cells, while in AKAP12 siRNA transfected cells,
mRNA expression decreased by 38% and protein levels decreased by 32%.
However, atRA treatment of AKAP12 siRNA transfected cells still caused a 4.4
fold increase in AKAP12 mRNA levels compared to control siRNA transfected
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cells without RA treatment.

Interestingly, treatment of AKAP12 siRNA

transfected cells treated with atRA resulted in a 51% increase in AKAP12 protein
compared to control siRNA transfected cells; however, when this is change is
compared to cells transfected with siRNA to AKAP12, there is a 2.2 fold change
in protein levels.

Figure 3.8A.
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Figure 3.8B.
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Figure 3.8D.
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Figure 3.8. Ability of AKAP12 siRNA to decrease AKAP12 mRNA and protein.
WM3248 and B16 cells were transfected with control siRNA and AKAP12
siRNA for 48h then split, reseeded, and allowed to grow for another 48 hours.
For B16 cells, appropriate plates of cells were treated with 1x10-7M atRA 6 hours
after seeding. After 48h of growth, triplicate plates of cells were harvested for
RNA and protein measurements.

A representative experiment is shown.

Experiments were performed a minimum of three times with similar results. A)
WM3248 AKAP12 mRNA levels, B) WM3248 protein levels, C) B16 AKAP12
mRNA levels, D) B16 AKAP12 protein levels. (∗ = p <0.05, • = p <0.001
compared to control)

Next, WM3248 human melanoma cells were assayed for their invasive
properties. After 48 hours of transfection with control siRNA and AKAP12
siRNA to allow for a decrease in the levels of AKAP12 RNA and protein, cells
were split and reseeded for the invasion assay. After 48 hours, there was a 44%
increase in the amount of invasive cells in the AKAP12 siRNA treated cells
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compared to control siRNA transfected cells (Figure 3.9A). Images clearly show
the increase in invasive cells. Figure 3.9B shows the amount of invasive cells in
the control siRNA transfected cells, while figure 3.9C shows the amount of
invasive cells in siAKAP12 transfected cells.

Figure 3.9A.
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Figure 3.9. Effect of decreasing AKAP12 levels on invasion in WM3248 human
melanoma cells. Cells were transfected with control siRNA and AKAP12 siRNA
for 48h, then split and reseeded into triplicate sets of wells for the CytoSelect
Invasion assay, which was performed according to manufacturer’s protocol. At
48 hours of incubation, invasive cells were photographed, harvested and counted.
A representative experiment is shown.

These experiments were repeated a

minimum of three times with similar results. A) Relative number of invasive cells
expressed as a percent of cells transfected with control siRNA B) Image of
WM3248 cells transfected with siControl, C) Image of WM3248 cells transfected
with siAKAP12. (∗ = p <0.05 compared to control)

Next, the effect of decreasing AKAP12 expression on the invasive properties
of B16 melanoma cells was determined. Cells were transfected with control
siRNA or AKAP12 siRNA 48h before reseeding the cells into the invasion assay.
Treatment of cells transfected with control siRNA plus atRA had a 37% decrease
in the number of invasive cells compared to control siRNA transfected cells
receiving vehicle (Figure 3.10A).

However, when AKAP12 levels were

decreased due to transfection with AKAP12 siRNA, there was a 28% increase in
the amount of invasive cells relative to control siRNA transfected cells.

In

siAKAP12 transfected cells treated with atRA, there was a 19% decrease in the
number of invasive cells compared to control siRNA transfected cells.
Comparing control siRNA transfected cells treated with atRA to AKAP12 siRNA
transfected cells treated with atRA there were 18% more invasive cells when
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AKAP12 levels are decreased. Photographic images also show the change in the
amount of invasive B16 cells. The image in Figure 3.10B shows the amount of
invasive cells after transfection with control siRNA, Figure 3.10C is an image of
the invasive cells after transfection with control siRNA and treatment with 1x107

M atRA. Note the reduced number of invasive cells. Figure 3.10D is an image

of invasive cells after transfection with siAKAP12, note the larger number
compared to image B.

Figure 3.10E is an image of invasive cells after

transfection with siAKAP12 and treatment with 1x10-7M atRA.

Figure 3.10A.
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Figure 3.10. Effect of decreased AKAP12 levels on B16 mouse melanoma cells.
B16 cells were transfected with control siRNA or AKAP12 siRNA for 48h, then
split and reseeded into triplicate wells of the CytoSelect Invasion Assay, which
was performed according to manufacturer’s protocol.

Control samples were

treated with DMSO and RA treated samples received 1x10-7M atRA. After 48
hours, invasive cells were photographed, harvested and enumerated.

A

representative experiment is shown. Experiments were repeated a minimum of
three times with similar results. A) Number of invasive cells relative to control,
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B) cells transfected with control siRNA, C), cells transfected with control siRNA
then treated with 1x10-7M atRA, D) cells transfected with AKAP12 siRNA, E)
cells transfected with AKAP12 siRNA then treated with 1x10-7M atRA. (∗ = p
<0.05 compared to control)

Effect of AKAP12 downregulation on anchorage-independent
growth in B16 mouse melanoma cells.
B16 cells were used to investigate the potential involvement of AKAP12 in
regulating anchorage-independent growth due to their atRA sensitivity and their
ability to form numerous colonies quickly in soft agar.

WM3248 human

melanoma cells were not used for this assay because they are unable to form
colonies until at least 7 days after the start of the assay, a time at which the effect
of AKAP12 siRNA was lost.

Anchorage-independent growth was measured

using the Cyto-Select 96-Well Cell Transformation Assay. B16 cells were
transfected with control siRNA and AKAP12 siRNA for 48 hours before
reseeding into the transformation assay. At 48 hours of incubation in this assay
there was a 31% decrease in colony formation in cells transfected with control
siRNA plus treatment with 1x10-7M atRA relative to cells transfected with control
siRNA, but not treated with atRA (Figure 3.11A).

In cells transfected with

AKAP12 siRNA, colony formation increases 70% compared to cells transfected
with control siRNA. The cells transfected with AKAP12 siRNA and then treated
with 1x10-7M atRA had a similar amount of anchorage-independent growth
relative to control siRNA transfected cells.
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Photographic images show the

changes in soft agar colony formation. Figure 3.11B is an image of colony
formation in control siRNA transfected cells and Figure 3.11C is an image of
colony formation after transfection of control siRNA and a 48h treatment with
1x10-7M atRA. Note the reduced number and smaller colonies. Figure 3.11D is
an image of colony formation after 48h transfection with AKAP12 siRNA. This
image shows larger and more abundant colony formation. Figure 3.11E is an
image of colony formation in AKAP12 siRNA transfected cells and treated for
48h with 1x10-7M atRA.

This image verifies that colony formation is still

reduced in these cells.

Figure 3.11A.

Amount of Colony Forming Cells
Represented as % of Control

48h Anchorage-Independent Growth Assay on B16
Mouse Melanoma Cells (96h siRNA Transfection)

∗

200

170

180
160
140
120

114

∗

100

100

69

80
60
40
20
0
siControl

siC+RA

- 93 -

siAKAP12

siA+RA

B. siControl transfected B16 cells

C. siControl transfected B16 cells + RA

D. siAKAP12 transfected B16 cells

E. siAKAP12 transfected B16 cells + RA

Figure 3.11. Effect of decreased levels of AKAP12 on anchorage-independent
growth. B16 cells were transfected with control siRNA and AKAP12 siRNA for
48h, then split and reseeded into triplicate wells for the CytoSelect 96-Well
Cell Transformation Assay, performed according to manufacturer’s protocol.
Control transfected siRNA cells and AKAP12 siRNA transfected cells received
either DMSO or 1x10-7M atRA. After 48h of growth, cells were photographed,
harvested and assayed for anchorage-independent growth.

A representative

experiment is shown. Experiments were repeated a minimum of three times.
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Each repeat contained a minimum of 3 sample repeats per assay. A) Amount of
soft agar colony growth relative to control cells, B) cells transfected with control
siRNA, C) cells transfected with control siRNA and treated with 1x10-7M atRA,
D) cells transfected with AKAP12 siRNA, E) cells transfected with AKAP12
siRNA and treated with 1x10-7M atRA. (∗ = p <0.05 compared to control)

We also examined anchorage-independent colony formation after 72 hours of
incubation (120 hours after transfection with control siRNA and AKAP12
siRNA). Cells transfected with control siRNA and treated with 1x10-7M atRA for
72 hours still showed a 40% decrease in colony formation (Figure 3.11A). In
AKP12 siRNA transfected cells, colony formation was only increased by 25%
(Figure 3.12A), while a 72 hours treatment of AKAP12 siRNA transfected cells
with 1x10-7M atRA causes a 28% decrease in colony formation, compared to cells
transfected with control siRNA. However, if this change is compared to what is
seen in AKAP12 siRNA transfected cells, the decrease in colony formation is
58%, which is a greater decrease than what is seen in control siRNA transfected
cells treated with atRA.
We also examined RNA and protein levels in B16 cells 120 hours after
transfection with control siRNA or AKAP12 siRNA. QRT-PCR analysis shows
that after 72 hours of 1x10-7M atRA treatment in control siRNA transfected cells
there is a 9.62 fold induction of AKAP12 mRNA (Figure 3.12B).

Cells

transfected with AKAP12 siRNA show only a 22% decrease in AKAP12 mRNA
relative to cells receiving control siRNA, indicating that the siRNA is losing its
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effect. However, AKAP12 siRNA transfected cells treated with 1x10-7M atRA
had a 5.93 fold increase in AKAP12 mRNA, a reduction of almost 3.7 fold
relative to control cells treated with atRA. Western blot analysis of protein levels
show that while mRNA levels are very high in siControl+atRA treated cells,
protein levels are only increased 60%. In cells transfected with AKAP12 siRNA
there is surprisingly an increase in AKAP12 protein relative to control siRNA
transfected cells (49%) (Figure 3.12C). Even though atRA could only increase
AKAP12 protein levels by 60% in control cells, in cells receiving AKAP12
siRNA prior to atRA treatment there is a 3.1 fold increase in AKAP12 protein
levels.

Figure 3.12A.
B16 Mouse Melanoma Cells - 72h AnchorageIndependent Growth Assay
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Figure 3.12B.
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Figure 3.12C.
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Figure 3.12. Effect of AKAP12 siRNA treatment on B16 mouse melanoma
anchorage-independent growth 72 hours after treatment (mRNA and protein
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levels are also included). B16 cells were transfected with control siRNA or
AKAP12 siRNA for 72 hours, then split and reseeded into triplicate wells per
treatment group for the CytoSelect 96-Well Cell Transformation Assay, which
was performed according to manufacturer’s protocol. Cells were treated with
DMSO or 1x10-7M atRA.

After 72h of growth, cells were photographed,

harvested and assayed for anchorage-independent growth. A representative assay
is shown. The experiment was repeated two additional times with similar results.
A) 72hour anchorage-independent growth assay, B) AKAP12 mRNA levels 120
hours after transfection, C) AKAP12 protein levels 120 hours after transfection.
(∗ = p <0.05, • = p <0.001 compared to control)
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Discussion
Cutaneous malignant melanoma (CMM) is the most serious form of skin
cancer and its incidence is steadily increasing. The ability of retinoids to regulate
melanoma cell growth and differentiation has been well documented, yet research
has also shown that as melanoma progresses from RGP to VGP to Met, cells lose
their responsiveness to atRA (Jacob, et. al., 1998; Niles, et. al., 2003; Fan, et. al.,
2010). We lack a complete understanding as to how atRA exerts its anti-cancer
effects and don’t fully understand why advanced stage melanomas become so
resistant to the effects of atRA.
Gene expression profiling using DNA microarrays was performed on control
and atRA treated B16 mouse melanoma cells to help discover new target genes of
atRA. We identified AKAP12 as a novel, atRA target gene.
AKAP12 is an anchoring protein that is involved in assembly and
compartmentalization of multi-protein complexes, thus coordinating and directing
the transduction of multiple signaling pathways.

The development and

progression of CMM involves many molecular and genetic changes affecting
multiple signaling pathways that regulate growth, metabolism, motility and
apoptosis. AKAP12 may play a pivotal role in regulating these changes as it lies
at a central junction where the regulation of these pathways converges. However,
the role of AKAP12 in the function of melanocyte and melanoma biology is
currently not known.
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AKAP12/Gravin/SSeCKS is believed to be a Type II tumor suppressor gene,
because its protein and RNA expression are downregulated in many epithelial
derived tumors, and its re-expression in cancer cells has been demonstrated to
suppress various parameters of tumor function.

Research from Dr. Irwin

Gelman’s laboratory has shown that over-expression of AKAP12/SSeCKS in
NIH3T3 cells causes inhibition of cell growth by promoting G1 phase arrest
through binding and regulation of cyclin D activity (Gelman, 2002; Lin, et. al.,
2000).

It also promotes re-organization of the actin-based cytoskeleton and

induces cell flattening (Nelson and Gelman, 1997; Gelman, et. al., 1998; Gelman,
et. al., 2000; Xia and Gelman, 2002; Cheng, et. al., 2007). In addition, ectopic
AKAP12 expression inhibits podosome formation and metastatic progression in
human prostatic cancer (Lin and Gelman, 1997; Xia, et. al., 2001; Gao and
Gelman, 2006). The AKAP12 gene locus on chromosome 6 contains a deletion
hotspot and aberrations on chromosome 6 are important in CMM progression.
Vertical growth phase and metastatic melanomas also have nonrandom
abnormalities on chromosome 6 (Liotta, et. al., 1987).

These observations

suggest that AKAP12 may play a role in melanoma progression.
There are only two published reports that have examined AKAP12 expression
in melanoma cells. Hacker et al (2008) compared spontaneous vs UVR-induced
mouse melanoma. There were 264 genes differentially expressed between these
two groups. qRT-PCR verified that AKAP12 expression was downregulated in
the UVR-induced mouse melanomas.

In the second report, 5-aza-2-

deoxycytidine, a DNA methylation inhibitor and trichostatin A, an inhibitor of
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histone deacetylase were used to determine genes that were reactivated in
melanoma cell lines (Bonazzi, et. al., 2009). Although AKAP12 was one of these
genes, its re-expression did not correlate with a high proportion of promoter
demethylation.
Recently Streb et al (2011) found that atRA stimulates AKAP12 expression
in vascular smooth muscle cells. In this study, atRA specifically targeted the
induction of the AKAP12β isoform.

Based upon an early induction of the

AKAP12 mRNA (3h) and the presence of a RARE in the promoter of AKAP12, it
was concluded that AKAP12β is a retinoid responsive immediate-early gene.
This finding is in contrast to our results in melanoma cells, where AKAP12
expression was not induced until 24 hours after atRA treatment and no RARE’s
were identified in the AKAP12α promoter region.
The induction of AKAP12 by atRA is significantly correlated with the ability
of this retinoid to inhibit melanoma cell proliferation.

There is limited

information on the ability of AKAP12 to regulate proliferation in various cancer
cell lines. However, several studies suggest that it plays an important role in other
aspects of tumor biology, such as cancer cell invasiveness and metastatic
properties (Lin and Gelman, 1997; Gao and Gelman, 2006; Su, et. al., 2010).
Failure of atRA to increase AKAP12 expression is associated with an inability to
inhibit melanoma cell growth. Although these data suggest that high levels of
AKAP12 may also mediate atRA induced growth inhibition of melanoma cells,
some cell lines such as WM3248 can be induced by atRA to produce high levels
of AKAP12, but are relatively unaffected by the growth inhibitory effects of
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atRA. One possibility for this anomaly is that the retinoic acid nuclear receptor
that mediates the induction of AKAP12 expression is different from the one that
mediates inhibition of proliferation.
To address how atRA was inducing the expression of AKAP12, I performed a
computer analysis of transcription factor binding sites within the AKAP12
promoter. While I did not find any RARE site, I did identify several putative AP1 sites.

Since our laboratory previously reported that atRA increases AP-1

activity in mouse melanoma cells (Desai and Niles, 1997; Huang, et. al., 2002), I
tested the hypothesis that atRA was increasing AKAP12 mRNA expression
through its ability to stimulate AP-1 activity. AP-1 activity was increased in
several of our human melanoma cell lines when treated with atRA. This finding
reproduces what we previously reported in B16 melanoma cells.
I tested whether AP-1 mediates the atRA induction of AKAP12 in B16 cells by
inhibiting AP-1 activity through the use of the dominant negative fos (A-fos).
The role of AP-1 in the regulation of AKAP12 expression in melanoma is
opposite to what we had hypothesized. Instead of mediating the increase in
AKAP12 in atRA-mediated melanoma cells, AP-1 acts as a negative regulator.
This conclusion is based on the findings that inhibition of AP-1 activity through
expression of a dominant-negative A-fos plasmid led to a higher degree of atRAinduced AKAP12 stimulation compared to cells with normal AP-1 activity. This
negative regulation of AKAP12 expression by AP-1 may be explained by the
location of its binding sites. The AKAP12 promoter can be subdivided into three
sections that contain a basal promoter region (-173 to +1), a modulator region (-
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588 to -174) and a negative control region (-4764 to -589) (Streb 2004). My in
silico analysis of the AKAP12 promoter revealed that the putative AP-1 binding
sites lie within the negative regulatory region (-4764 to -589). I postulated that
specific deletion or mutation of these sites will lead to enhanced stimulation of
AKAP12 expression by atRA.
This paradox of atRA-induced increase of a negative regulator of AKAP12
expression suggests that very high levels of AKAP12 might be detrimental to its
normal functioning in the regulation of signaling processes. I hypothesized that if
cellular AKAP12 levels remain too low, this may predispose the cell to an
enhanced proliferative state, augmenting the loss of controls on processes such as
cell adhesion and motility. In contrast, if AKAP12 levels are too high, signaling
molecules such as protein kinases are tightly sequestered by the AKAP12
scaffold, thus preventing the normal functioning of pathways.

If this latter

situation is not reversed it could lead to cell death.
Epigenetic factors are also involved in the control of AKAP12 expression.
Methylation of the AKAP12 promoter has been described and associated with
silenced or reduced expression of AKAP12 mRNA (Jin, et. al., 2008; Mardin, et.
al., 2010).

This mechanism may explain the lack of AKAP12 induction in

response to atRA treatment seen in WM1366 (VGP) melanoma cells.
Because AKAP12 is a “late” atRA regulated gene and does not contain any
discernable retinoic acid response elements, it is likely that an “early” atRA
directly-regulated gene is responsible for the stimulation of AKAP12 mRNA and
subsequently protein levels in mouse and human melanoma cells. My current
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working model for atRA regulation of AKAP12 is shown in Figure 13. In the
unstimulated state, there is basal expression of the AKAP12 gene and AP-1 may
be bound to some of its consensus sequences. Upon addition of atRA, the RAR
(retinoic acid receptor): RXR (retinoid X receptor) heterodimer complex is
activated and stimulates the expression of gene “X”. In addition, atRA stimulates
increased AP-1 activity. The expression of Gene “X” increases and binds to its
consensus sequence, most likely located in the basal promoter region or the
modulator region of the AKAP12 gene. While the binding of factor “X” induces
transcriptional activity of the AKAP12 gene, the binding of AP-1 works to repress
expression, restraining the overall production of AKAP12 mRNA and protein.
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Figure 13. Working model for atRA induction of AKAP12 gene activity in
melanoma cells. This diagram shows the promoter region of the AKAP12α gene.
A is the basal promoter region, B is the modulator region and C is the negative
control region. Numbers indicate the location of the AP-1 DNA binding sites.
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After addition of atRA, the activated RAR/RXR heterodimer binds to the retinoic
acid response element located in Gene X and induces its expression. In addition,
atRA also stimulates increased activity of the transcription factor AP-1. Gene X
may bind to a site located in the basal promoter or modulator region to induce the
expression of AKAP12. However, the increased activity and subsequent binding
of AP-1 to the regions located in the negative control region modulates the overall
level of AKAP12 expression.

To ascertain AKAP12 function in melanoma cell biology, WM3248 (human)
and B16 (mouse) melanoma cells were transfected with siRNA to AKAP12 in
order to decrease its expression. These treated cells and appropriate controls were
assayed for their ability to invade Matrigel basement membranes and grow in an
anchorage-independent manner.

AKAP12/SSeCKS/Gravin re-expression has

been shown to inhibit Matrigel invasion and soft agar colony formation in NIH3T3 fibroblasts and MLL prostate cancer cells (Lin 1997, Gao 2006, Su 2010).
The effect of AKAP12’s decreased expression on atRA’s ability to regulate
melanoma cell invasion and proliferation was also examined. AKAP12 knockdown in non-atRA treated WM3248 and B16 cells results in increased invasive
properties. AKAP12 knock-down also increased anchorage-independent growth
in B16 melanoma cells. Although atRA treatment inhibits invasion and soft agar
colony formation in B16 cells, and the down-regulation of AKAP12 expression
does somewhat antagonize the ability of atRA to inhibit invasive and proliferative
properties, results were not as significant as we expected. One possibility to
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explain these findings is the amount of time (4-5 days after siRNA transfection)
required to measure anchorage-independent growth. This prolonged time leads to
decreased capacity of the siRNA to downregulate AKAP12 expression, allowing
atRA to overcome the effects of the silencing RNA.
It would be interesting to determine the biological effect of over-expressing
AKAP12 in melanoma cells, such as WM1366, which are unresponsive to the
effects of atRA and exhibit only low levels of AKAP12 induction after atRA
treatment.

Overexpression of AKAP12 was attempted using two different

plasmids; pEGFP-Gravin and pcDNA3.1/V5/His-Gravin. These plasmids were
submitted to us by Dr Bryon Grove, at the University of North Dakota, School of
Medicine. The vectors were 4.7 and 5.4kb respectively, while the Gravin insert
was 5.343kb. Due to the large size of the Gravin insert, I found it very difficult to
achieve a reasonable amount of expression in any of the melanoma cell lines
tested with these plasmids.
In conclusion, I have demonstrated that atRA regulates the expression of
AKAP12 in mouse melanoma and in human melanocytes, and to varying degrees,
human melanoma cells. Further, the induction of AKAP12 is tightly linked to
inhibition of melanoma cell proliferation by atRA.

However, additional

experiments are needed in order to understand how AKAP12 expression is being
regulated. My studies also suggest that AKAP12 has a tumor suppressive role in
melanoma biology, regulating metastatic and proliferative properties of melanoma
cells.
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Chapter 4: Conclusion
During the process of melanoma tumor growth and progression, many genes
become deregulated and contribute to its lethality.

The regulation of gene

expression requires a complex network of positive and negative growth factors,
signaling pathways, and transcription factors. Transcriptional regulation of genes
in melanoma is a multifaceted process that over-rides the normal melanocyte
signaling pathways and there is a powerful association between signal
transduction pathways and the activation of transcription factors that are involved
in coordinating gene transcription. Transcription factors play a fundamental role
in controlling the activity of genes that regulate physiological functions such as
cell

growth,

survival,

apoptosis,

energy

metabolism,

inflammation,

differentiation, invasion, and metastasis in melanoma cells (Poser and Bosserhoff,
2004).
To help identify the key regulatory factors that contribute to melanoma
aggressiveness, a comparative analysis of gene expression data sets from the
NCBI GEO database using melanoma, basal cell carcinoma and seven other
cancer types was performed. In this analysis, advanced VGP melanoma had the
highest number of differentially expressed genes (Xu, et. al., 2012). There is also
an upregulation of key genes involved in fatty acid metabolism (β-oxidation), cell
invasion and metastasis.
Although available technology can identify the changes in gene expression
taking place during melanoma progression, as well as during specific treatment
protocols, it is important to address the cause of these gene expression changes.
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Because transcription factors are major players in this mechanism, we need to
know what role they play in altering the expression of targeted genes during the
progression of melanoma.
My research centered on the activity of two transcription factors that regulate
key genes involved in melanoma progression. They are members of a superfamily of ligand-activated transcription factors that include the RAR’s, RXR’s,
PPAR’s, LXR’s, FXR’s, thyroid receptor and Vitamin D receptor. The first part
of my thesis work investigated the biological effect of PPARα/γ activation in B16
mouse melanoma cells, and the second part examined the expression and function
of an indirect target gene of RAR activation, AKAP12. Both PPARs and RARs
induce gene activity through a similar mechanism and have been shown to
regulate the expression of genes involved in cell growth and differentiation.
PPARs are transcription factors that regulate genes involved in glucose and
fatty acid metabolism.

They also regulate pathways controlling cellular

proliferation, differentiation, tumor promotion, apoptosis and the immune
response. Ligands that activate PPARs have chemoprevention effects and inhibit
growth in several different types of cancer cells (Sertznig, et. al., 2007; Sertznig,
et. al., 2010). I therefore investigated the role of PPARs in regulating melanoma
cell growth.
The results of my experiments show that B16 mouse melanoma cells have
increased expression of PPARα and γ protein, but the growth of melanoma cells
treated with PPAR agonists was only moderately inhibited and PPARγ agonists
were more effective at inhibiting proliferation than PPARα agonists. In addition,

- 114 -

there is some problem with detecting the ability of PPARs to initiate gene
transcription. I was not able to detect a measurable level (lack of reporter gene
activity) of endogenous receptor, indicating that there is some problem with
regulating the expression of target genes. This decrease in transcriptional activity
might be due to the constitutive activation of the mitogen-activated kinase
pathway, inducing phosphorylation of specific serines by ERK1/2, located in the
N-terminal ligand-independent activation domain of the PPARs.

This

phosphorylation induces a conformational change in the protein that hinders its
ligand binding ability and downregulates its activity. The reason for this level of
regulation could be due to PPARs ability to activate the expression of genes
involved in inhibition of the cell cycle. More investigation is needed to determine
how alteration in PPARs may contribute to melanoma proliferation.
Unfortunately, there are few new articles that have addressed the issue of PPAR
function in melanoma since the publication of our work.
There are reports of PPAR agonists having effects on metastatic properties and
tumor proliferation. Grabacka M, et.al., (2006), demonstrated that activation of
PPARα with fenofibrate inhibited mouse and human melanoma cell invasion and
soft agar growth. Also, in mouse xenograft models of melanoma, mice were
given either the PPARγ agonist rosiglitazone; a RXR agonist; or a combination of
the two. Melanoma tumor growth was significantly inhibited by either ligand
alone and the combination had an additive effect (Klopper, et. al., 2009). These
results show that PPARγ agonists can still be effective inhibitors of melanoma
cell proliferation.
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For the second part of this project, my research was focused on a newly
identified indirect target gene of RAR activation that had not been previously
examined in melanoma cells. This gene, AKAP12, has been characterized in
other cancer cell lines, especially prostate (Xia, et. al.,2001), as being a major
regulator of signal transduction pathways that control cell adhesion and oncogenic
growth through its binding and sequestering of many different second
messengers. Currently, there are no publications reporting the atRA regulation of
AKAP12 expression in melanoma cells, or that address its role in melanoma cell
biology.
The majority of information on AKAP12 and cancer has come from work done
by Dr. Irwin Gelman’s laboratory at the Roswell Park Cancer Institute, through
the use of fibroblasts and prostate cancer cell lines. In Ras-transformed NIH3T3
fibroblasts, downregulation of SSeCKS increased soft agar colony formation and
Matrigel invasiveness (Lin and Gelman, 1997). Re-expression of SSeCKS in
MLL prostate cancer cells suppresses formation of lung metastasis and suppresses
the expression of vascular endothelial growth factor (VEGF), hypoxia-inducible
factor-1α (HIF-1α), and platelet-derived growth factor receptor β (PDGFRβ).
SSeCKS was shown to suppress the formation of metastatic lesions through
inhibition of VEGF expression and induction of soluble anti-angiogenic factors.
This inhibits neovascular formation induced by tumor cells at peripheral sites (Su,
et. al., 2006). SSeCKS-knockout mice develop prostate hyperplasia, suggesting
that these mice have increased susceptibility for oncogenic transformation
(Akakura, et. al.,2008).

In nude mice injected with MLL cells containing a
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tetracycline regulated SSeCKS expression vector, re-expression severely
decreased the formation of secondary lung metastasis, indicating that loss of
SSeCKS plays a major role in the metastatic progression of human prostate cancer
cells (Xia, et. al., 2001). In addition, the re-expression of SSeCKS in NIH3T3
cells suppresses podosome formation and decreases Matrigel invasiveness.
Pososomes are actin-rich structures commonly found in cancer cell lines and are
believed to assist in the invasive properties involved in metastasis of tumor cells.
SSeCKS aids in the suppression of oncogenisis by re-establishing the normal
actin-based cytoskeletal architecture (Gelman and Gao, 2006).
My research shows that, not only do mouse and human melanoma cells
express AKAP12, its expression is regulated by atRA. During my research on
AKAP12, I also made a novel finding that the transcription factor AP-1 is a
negative regulator of AKAP12 expression. Functional assays for quantifying the
invasive and anchorage-independent growth properties of mouse and human
melanoma cells showed that when AKAP12 expression was decreased, invasion
and soft agar colony formation was significantly increased. However, knockdown
of AKAP12 in melanoma cells treated with atRA only partially antagonized the
ability of this retinoid to inhibit Matrigel invasion and soft agar colony formation.
The AKAP12 siRNA could not sufficiently decrease the strong atRA induction of
AKAP12 enough to establish if there were changes in Matrigel invasion and
anchorage-independent growth. Therefore, it is still possible that atRA inhibits
these melanoma activities through other mechanisms in addition to stimulating the
expression of AKAP12.

I hypothesize that AKAP12 may play a tumor
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suppressive role in melanoma biology through coordinating signaling pathways
that prevent metastasis and anchorage-independent growth.
The ability of AKAP12 to regulate these various pathways stems from its
function as a scaffolding protein. This protein works to sequester and inhibit the
activity of many different enzymes, including those involved in transducing
signals through the cytoplasm of cells, events commonly initiated at the cell
membrane. The ability of AKAP12/SSeCKS/Gravin to associate with both the
plasma membrane and the actin cytoskeleton places this protein at a position
where it can have direct control over regulating the activity of various signaling
pathways and the actin based cytoskeletal architecture. Many of these pathways
regulate proliferation, differentiation, survival and metastatic properties (Gelman,
2002).

Figure 4.1 Model for AKAP12 scaffolding functions. During G0 or the early G1
phase of the cell cycle, the AKAP12 protein sequesters key signaling proteins
such as PKA, PKC, calmodulin (CaM), phosphatase 2B (PP2B), and cyclin D
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(CyD). After mitogenic stimuli, AKAP12 is rapidly phosphorylated by PKC,
inducing a conformational change that leads to the release of the various enzymes
and translocation of AKAP12 to the endoplasmic reticulum (ER) in peri-nuclear
area. This process leaves all of the enzymes free to become active themselves and
to regulate the activities of a variety of their substrates. The change in AKAP12s
ability to interact with actin, as well as its various binding proteins, enable the cell
to undergo changes in shape more easily (formation of podosome), which is
necessary for invasion and metastasis.

Most melanoma cells harbor mutated proteins, such as NRAS and BRAF, that
constitutively activate the MAPK pathway. Evidence suggests a link between the
MAPK pathway, the ability of AKAP12/SSeCKS to bind and regulate the activity
of protein kinase C (PKC), and cancer cell invasiveness (Su, et. al., 2010). PKC
is a serine/threonine protein kinase that plays a role in regulating many cellular
functions including cell growth and differentiation.

AKAP12 suppresses

metastatic motility in MAT-LyLu (MLL) prostate cancer cells by inhibition of the
RAS/RAF/MEK/ERK1/2 pathway through direct binding of PKC (Su, et. al.,
2010). Re-expression of SSeCKS in MLL cells causes a 50-65% decrease in total
PKCα activity, yet there is no change in total PKCα expression.

This is

interesting, because our laboratory has previously shown that RA induces a 6-8
fold induction of PKCα mRNA and protein, and a 4-fold induction of AP-1
activity (Desai and Niles, 1997; Huang, et. al., 2002). In addition, only the PKCα
protein, but not enzyme activity, was required for the RA-induced AP-1 activity
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seen in live melanoma cells. The atRA stimulation of AP-1 activity contributes to
growth arrest and differentiation. Treatment of B16 mouse melanoma cells with
the PKC enzyme inhibitor bisindoylmaleimide did not block the RA response
(Desai and Niles, 1997). Also, over-expression of PKCα in these cells resulted in
a more differentiated phenotype (Gruber, et. al., 1992). From this information
and my investigation of AKAP12 expression and function, I suggest that the
increase in AKAP12 expression seen in RA treated melanoma cells is coupled to
an increase in PKCα expression. This increase in PKCα protein expression seen
in melanoma cells may be necessary for AKAP12’s normal functioning as a
scaffolding protein. PKCα activity is not needed because AKAP12 is able to bind
and block its ability to function as a kinase protein.

- 120 -

- 121 -

Figure 4.2. Model of AKAP12 scaffolding function in melanoma cells before
and after treatment with atRA. In melanoma cancer cells, there are decreased
levels of AKAP12 protein. Also, these cells are highly proliferative, with a higher
fraction of cells in the G2/S phase of the cell cycle relative to normal
melanocytes.

The AKAP12 protein becomes positioned at the (endoplasmic

reticulum) ER near the nucleus of the cell, not at the cell membrane where it
would normally be located. The protein Cyclin D (CyD) has also translocated to
the nucleus, because of its involvement in cell cycle progression. The enzymes
PKA, PKC, CaM, and PP2B, are free to become active, regulating the activity of
their substrate proteins, and in turn the activity of various signaling pathways.
Retinoic acid works to inhibit melanoma cell growth by first halting proliferation
at the G1 phase of the cell cycle. It is also responsible for increased expression
levels of the proteins PKC and AKAP12 (as an indirect target gene), and for
increased activity of the transcription factor AP-1.

As the cells halt their

proliferation at G1, cyclin D translocates from the nucleus to the cell membrane to
become bound to AKAP12. PKC protein levels also increase, similar to those of
AKAP12. The docking of PKC to the AKAP12 scaffolding protein is essential
for the ability of AKAP12 to bind all of the appropriate proteins in the correct
conformation. The re-localization of cyclin D and increased PKC protein levels,
combined with increased AKAP12 protein, allow AKAP12 to function as a
negative mitogenic regulator, sequestering and inhibiting the enzymatic properties
of the various proteins.
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PKC can also influence RA signaling by altering the stability of the RARα
protein. Activation of PKC in mouse melanoma cells leads to an increase RARα
protein levels, while downregulation of PKC diminishes RARα protein half-life
and markedly inhibits ligand-independent transcriptional activity (Boskovic, et.
al., 2002). Regulation of RARα expression and activity may be one possible way
of influencing the RA-induced expression of AKAP12.
Another possible mechanism for AKAP12 regulation of the melanoma
phenotype is though its ability to regulate G-protein coupled receptor (GPCR)
activity (Shih, et. al., 1999). The melanocortin-1 receptor (MC1R) is a G-protein
coupled receptor that is involved in melanoma function and development.
Individuals with mutations in this receptor produce more of the red/yellow
pigment pheomelanin, than the black photo-protective pigment eumelanin.
Because of the decreased eumelanin expression, these individuals usually have
fair skin and light colored hair, and are more sensitive to UV induced DNA
damage. Stimulation of GPCRs involves phosphorylation of the receptor, which
is a critical element of agonist-induced desensitization, leading to internalization
of the receptor for recycling.

This process includes the involvement of the

enzymes PKA, G protein-coupled receptor kinases (GRKs) and the adaptor
molecule β-arrestin. The activity of MC1R is regulated by the agonists ACTH
(adrenocorticotropic hormone) and αMSH (melanocyte stimulating hormone),
while ASIP (agouti signaling peptide) is an antagonist.

Receptor activation

induces the activity of adenylate cyclase, resulting in increased production of
cAMP. This cyclic nucleotide is necessary for PKA activation. AKAP12 not
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only binds the kinases PKA and PKC, as well as phophatase 2B (PP2B), but can
also directly associate with the GPCR. The physical association of AKAP12 to
the

β2-GPCR

affects

signaling

through

regulation

of

agonist-induced

desensitization of the receptor. The protein phosphatase PP2B plays a critical role
in resensitization due to its ability to dephosphorylate the receptor (Shih, et. al.,
1999).

Once desensitization and internalization of the MC1R is complete,

AKAP12 plays a crucial role in resensitization (dephosphorylation) and recycling
of the receptors back to the cell membrane. Therefore, the reduced AKAP12
expression in melanoma cancer cells may influence and downregulate MC1R
activity, by impeding recovery from agonist-induced desensitization (Shih, et. al.,
1999; Tao, et. al., 2007; Tao and Malbon, 2008).
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Figure 4.3.

Model for the regulation of melanocortin 1 receptor (MC1R)

signaling by AKAP12. AKAP12 provides docking sites for protein kinase A
(PKA), protein kinase C (PKC), and phosphatase 2B (PP2B) and many other
enzymes and adaptor molecules that are not shown. AKAP12 also associates with
the MC1R. After the MC1R binds its agonist, this leads to activation of the
receptor and the small Gα protein (GαS). GαS is responsible for the activation of
adenyl cyclase, which converts ATP to cAMP. PKA needs to bind cAMP to
become active. Once activated, PKA will phosphorylate specific sites on the
receptor and the AKAP12 protein. This phosphorylation will markedly enhance
the binding of AKAP12 to the receptor. The enzyme PP2B is responsible for
dephosphorylation of sites located on the AKAP12 scaffolding protein and the
MC1R receptor. This process is critical for AKAP12 ability to mediate the
resensitization and recycling of the internalized MC1R back to the cell membrane.

There are numerous avenues of the AKAP12 project that need to be explored.
The regulation of AKAP12 gene expression and function in normal melanocytes
needs to be determined. Other research questions include: What is the identity of
factor “X”, i.e. the atRA direct target gene that is responsible for induction of
AKAP12 expression after treatment of melanocytes or responsive melanoma cells
with atRA? Second, is there a difference in subcellular location of AKAP12 in
the melanoma cells compared to the normal human melanocytes? An altered
location of AKAP12 in melanoma cells could change the function of this
scaffolding protein. Third, how would over-expression of AKAP12 in a cell line
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such as WM1366 melanoma cells, a rapidly growing, atRA resistant cell line,
change the physiology of these cells??

I was unable to successfully attain

overexpression of the AKAP12 gene in these melanoma cells. The cDNA coding
for this gene is approximately 5.4kb and is as large as or larger than the
expression vectors that were used to express the gene in melanoma cells. The
very large size of the plasmid impeded its transfection efficiency. However, an
adenoviral delivery system may be more successful in achieving high AKAP12
gene expression. Fourth, the WM3248 cells express very high basal levels of
AKAP12 and these levels are further induced by atRA, yet, these cells are only
moderately responsive to the growth inhibitory effects of atRA. Why is there a
strong induction of AKAP12 in cells that are more resistant to atRA-dependent
growth inhibition??

Last, mutation of sites encoding binding domains for

important signaling kinases located in the N-terminal region of the protein can
give insight into how AKAP12 regulates these pathways. The answers to the
questions listed above will provide a much deeper insight into the role of
AKAP12 in melanocyte biology and could uncover therapeutic targets to
counteract its dysfunction in human melanoma.
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